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ABSTRACT
Embryonic Stem (ES) cells are the in vitro derivatives of the inner cell mass of a
developing embryo, and exhibit the property of pluripotency, which is the ability of
a cell to give rise to all cell lineages of an organism.  Therefore, these cells hold
great promise in the treatment of several degenerative diseases through patient-
specific cell-based therapy.  Consequently, a detailed knowledge of the factors
regulating ES cell identity is required in order to exploit this therapeutic potential.
In order to address this subject, genome-wide location analysis (or ChIP-chip)
has been used to identify downstream genes that are bound, and potentially
regulated by the key pluripotency transcription factors, Oct4 and Nanog.  The
data from this study have also been compared and integrated with Oct4 and
Nanog DNA binding data obtained in a different study using the ChIP-PET
technology.  In order to gain further insight into the mechanisms by which the
transcription factor Nanog regulates its downstream targets, an attempt at
identifying proteins interacting with Nanog has also been described.
Research on ES cells has been plagued with ethical controversies since the
creation of these cells requires the destruction of embryos.  Recent studies have
reported the reprogramming of somatic fibroblasts into an ES cell-like induced
pluripotent state (iPS) by virus-mediated transduction of four transcription
factors— Oct4, Sox2, c-Myc and Klf4, thereby circumventing the use of embryos
in producing pluripotent cells.  In these studies, selection for the activation of the
markers Oct4 or Nanog led to completely reprogrammed cells, but selection for
fbx15, a downstream target of Oct4, resulted in partially reprogrammed
intermediates.  An unresolved issue in the field was whether these intermediates
were obtained due to early drug selection in the case of fbx15 selection, or
because Fbx15 expression is not relevant to pluripotency.  Drug selection for
fbx15 activation at later time-points, and an examination of the methylation status
of the Oct4 locus of Fbx15-iPS cells suggests that the intermediates were
obtained due to early drug selection and not due to selection for fbx15.
Therefore, these studies have begun to elucidate a framework that governs ES
cell identity, and the mechanism by which a differentiated cell can be
reprogrammed into a pluripotent state.
Thesis Supervisor: Rudolf Jaenisch
Title: Professor of Biology
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Introduction
8(I) MOLECULAR CONTROL OF PLURIPOTENCY
Parts of this section have been adapted from a review: Boyer, L.A., Mathur, D.
and Jaenisch, R. (2006). “Molecular Control of Pluripotency.”  Current Opinion in
Genetics and Development 16(5): 455-62.
Developmental Potency and the Isolation of Embryonic Stem Cells
For more than a century, biologists have been fascinated with the subject of
developmental potency, which is the capacity of a cell to give rise to other cell
types.  The most versatile cell is the fertilized egg or zygote, which is totipotent
and can generate an entire organism along with the extra-embryonic tissues
necessary for development.  In the late 1800s, experiments done by Hans
Driesch on sea urchins demonstrated that this property of totipotency is also
present in the individual blastomeres of the 2- and 4-cell stage embryos (Driesch
1892).  As better techniques to manipulate embryos evolved, further work on
mammalian embryos showed that such potency is retained even in 8-cell stage
blastomeres (Tarkowski and Wroblewska 1967).  After this stage, the
developmental potential of the cells in the embryo becomes more restricted as
the outer cells generate the trophectoderm, an extra-embryonic tissue, and cells
on the inside contribute to the inner cell mass (ICM), which subsequently forms
the embryo proper (Ziomek and Johnson 1982; Ziomek, Johnson et al. 1982).
The cells of the ICM are therefore pluripotent since they can generate all the cell
lineages of an organism except the extra-embryonic tissues (Figure 1(a)).
9A remarkable discovery that had tremendous impact on developmental genetics
and medicine was the isolation of embryonic stem (ES) cells (Evans and
Kaufman 1981; Martin 1981; Thomson, Itskovitz-Eldor et al. 1998).  These cells
are derived from the ICM of a developing blastocyst, and mimic the pluripotent
abilities of their founder cells (Figure 1(a)).  Additionally, they have the capacity
to self-renew indefinitely in vitro, thereby offering a convenient model for studying
early development.  As further differentiation occurs during development, other
types of stem cells emerge in the organism.  Some of these, such as
hematopoietic stem cells, are multipotent and can generate all the cell types
within a specific lineage (Orkin and Zon 2008).  Others, like spermatogonial stem
cells, are unipotent since they can only form a particular type of cell (Cinalli,
Rangan et al. 2008).
Even though specialized stem cells offer great benefits for therapeutic purposes,
the pluripotent nature of ES cells gives them the great potential of being used in
a wider range of regenerative therapies, along with being valuable tools in
studying development and differentiation.  For instance, ES cells have been used
extensively in mammalian transgenics to study developmental phenomena and
model human diseases.  This technique involves targeting a DNA construct to
specific genomic loci via homologous recombination in ES cells.  These targeted
ES cells can be injected into developing blastocysts, which are then implanted
into a pseudo-pregnant female to generate chimeras.  The chimeras can then be
bred to wild-type strains to generate transgenic animals containing the targeted
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construct in their germ line.  This technique can also be exploited in the future to
correct for various genetic disorders, such as sickle cell anemia.  Additionally,
since ES cells can give rise to any of the cell lineages in an organism, they may
also be used in patient-specific cell-based therapies for treating degenerative
disorders, while avoiding problems with immune-rejection.  Aside from these
applications, based on the similarity between these cells and those of the ICM,
they hold great value as tools to study early development and lineage
commitment in vitro.
Given the wide range of applications that ES cells can be used for, a detailed
understanding of the mechanisms that enable propagation of these cells in a
pluripotent state, poised to execute a broad range of developmental programs, is
essential to realizing their therapeutic potential.  In metazoans, the establishment
and maintenance of lineage-specific gene expression programs are highly
conserved throughout evolution and are vital for development (de la Serna,
Ohkawa et al. 2006; Lin and Dent 2006).  External environmental factors can
also influence gene regulation (Smith 2001; Burdon, Smith et al. 2002; Boiani
and Scholer 2005).  It is of much interest to examine how genetic and epigenetic
factors control ES cell identity and influence the balance between pluripotency
and differentiation in mammals.
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Figure 1.  Core Transcriptional Regulatory Circuitry in Pluripotent Mouse
and Human ES Cell. (a) Embryonic stem (ES) cells are derived from the
pluripotent cells of the inner cell mass (ICM), which normally gives rise to the
embryo.  (b) Genomics studies have enabled the construction of a core
transcriptional regulatory network in ES cells, initiated by Oct4, Sox2, and Nanog.
This network reveals an integrated circuitry comprised of genes that specify the
development of both the extraembryonic and embryonic lineages.  Shown are a
few examples of the circuitry components in the mouse and human studies.
Boxes and circles indicate genes and proteins, respectively.  Arrows represent
interactions only, and not positive or negative effects.  Genes for which the
binding information with mouse Sox2 is available are marked with an asterisk.
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Genetic Control of Pluripotency in the Embryo and ES Cells
The homeodomain transcription factors Oct4 (also known as Pou5f1) and Nanog
have been identified as crucial regulators of pluripotency and are predominantly
expressed in pluripotent cell types.  These factors also regulate preimplantation
development in mammals, which is marked by two major differentiation events.
The first of these occurs when the outer cells of the morula differentiate into the
trophectoderm, which forms the chorion, the embryonic part of the placenta.  This
cell fate decision correlates with the expression of Oct4, since a loss of this
transcription factor results in differentiation of all cells into the trophoblast lineage
(Niwa, Miyazaki et al. 2000).  The second differentiation event occurs in the early
blastocyst, where certain cells from the ICM form the primitive endoderm, which
forms the yolk sac.  In addition to Oct4, the transcription factor Nanog plays a
critical role in this event.  The ICM of nanog-deficient embryos does not produce
an epiblast, and only generates primitive endoderm (Chambers, Colby et al.
2003; Mitsui, Tokuzawa et al. 2003).
Apart from the ICM, Oct4 and Nanog also play a vital role in maintaining the
pluripotent state of ES cells.  Loss of Oct4 causes inappropriate differentiation of
ES cells into trophectoderm, whereas overexpression of Oct4 results in
differentiation into primitive endoderm and mesoderm, suggesting that precise
Oct4 levels are necessary for pluripotency (Nichols, Zevnik et al. 1998; Niwa,
Miyazaki et al. 2000).  Oct4 can regulate gene expression by interacting with
other factors within the nucleus, including the high mobility group (HMG)-box
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transcription factor, Sox2 (Boiani and Scholer 2005).  Although Sox2 plays an
important role in the maintenance of pluripotency and lineage specification, its
expression is not restricted to pluripotent cells, because Sox2 is also found in
early neural lineages (Avilion, Nicolis et al. 2003).  ES cells lacking Nanog
spontaneously differentiate into primitive endoderm (Chambers, Colby et al.
2003; Mitsui, Tokuzawa et al. 2003).  Conversely, overexpression of Nanog
promotes self-renewal independently of the cytokine leukemia inhibitory factor
(LIF), which functions by activating the transcription factor Stat3 (Matsuda,
Nakamura et al. 1999).  Although the LIF-Stat3 pathway is dispensable in human
ES cells, recent functional analyses indicate an analogous role for Oct4 and
Nanog in these cells (Hyslop, Stojkovic et al. 2005; Zaehres, Lensch et al. 2005).
Thus, Oct4, Nanog and Sox2 are the earliest-expressed set of genes known to
maintain pluripotency.  Together these studies suggest that Oct4, Nanog and
Sox2 function in distinct pathways that might converge to regulate certain
common genomic targets.  It is likely that the interplay among these factors is
critical for early cell fate decisions.
The Balance between a Minimal Set of Lineage Specification transcription
factors might drive early cell-fate decisions
The simplest model for how Oct4, Nanog and Sox2 function is that they
collaborate with other transcription factors to specify a pluripotent state and thus
form the basis of a transcription factor hierarchy.  Consistent with this, the
balance between the levels of Oct4 and the Caudal-type homeodomain
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transcription factor Cdx2 has recently been shown to influence the first overt
lineage differentiation in the embryo (Niwa, Toyooka et al. 2005).  Oct4 and Cdx2
expression patterns become mutually exclusive during embryogenesis, owing, in
part, to their ability to reciprocally repress each other’s expression.  Oct4 is
associated with the establishment of the ICM, whereas Cdx2 expression is
necessary for trophectoderm development (Strumpf, Mao et al. 2005).  Oct4 is
lost from the outer cells of the morula that become fated for trophectoderm,
whereas Cdx2 expression is restricted to these cells.  Oct4 and Cdx2 also
regulate the T-box transcription factor eomesodermin (eomes), which, like Cdx2
is necessary for trophectoderm maintenance (Niwa, Toyooka et al. 2005).  These
studies suggest that the interaction between these factors is essential for the
segregation of the inner cell mass and trophectoderm lineages during
development.
A similar balance between Nanog and the transcription factors, Gata4 and Gata6
might be necessary for differentiation into primitive endoderm, a derivative of the
inner cell mass of the developing blastocyst.  Forced expression of Gata4 or
Gata6 in ES cells leads to differentiation into primitive endoderm, an effect similar
to that caused by the loss of Nanog function (Fujikura, Yamato et al. 2002;
Mitsui, Tokuzawa et al. 2003; Boyer, Lee et al. 2005).  Moreover, Gata4 and
Gata6 expression was upregulated in the absence of Nanog (Fujikura, Yamato et
al. 2002), indicating that Nanog acts as a repressor of differentiation.  Although
there has been no in vivo evidence of Nanog acting as a transcriptional activator,
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luciferase reporter assays indicate that Nanog can also activate transcription via
its C-terminal domain (Pan and Pei 2005).  Together, these studies suggest that
a minimal set of lineage-specific factors can drive early cell fate decisions (Table
1).  However, it is likely that other genetic, epigenetic and environmental factors
play an important role in this process.  It would be interesting, for instance, to
identify the factors that proteins like Nanog and Oct4 interact with to allow them
to act as transcriptional activators or repressors.  One such study has identified a
protein-interaction network for Nanog, although the relevance of individual
binding events to pluripotency needs to be validated (Wang, Rao et al. 2006).  A
similar approach to identifying factors associated with Nanog is also described in
the Appendix.
Transcriptional Regulatory Networks in Pluripotent ES Cells
Given that the factors orchestrating early cell fate decisions also regulate ES cell
pluripotency, Oct4, Nanog and Sox2 are thought to establish the initial genomic
state from which all other gene expression patterns are derived during
development.  Recent genomics studies have enabled the construction of
transcriptional regulatory networks in ES cells that provide a foundation for
understanding how Oct4, Nanog and Sox2 control pluripotency and influence
subsequent differentiation events.  Two studies have used chromatin
immunoprecipitation (ChIP) combined with genome-wide methodologies to map
the binding sites for Oct4 and Nanog throughout human and mouse ES cell
genomes (Boyer, Lee et al. 2005; Loh, Wu et al. 2006).  In the case of human ES
Table 1.  Gene Expression Analyses of Transcription Factors in ES Cell Pluripotency and Embryonic
Development.
Loss of Function PhenotypeTranscription
Factor
Protein Family Expression Pattern
Embryonic Development ES Cells
Gain of Function
Phenotype
in ES Cells
Oct4
Pit/Oct/Unc
protein family
oocytes, fertilized embryo,
ICM, epiblast, ES cells, EC
cells, germ cells
Embryonic lethality
(blastocyst stage),
differentiation of epiblast
into TE lineage
Loss of pluripotency,
differentiation into TE
lineage
Differentiation into
primitive endoderm
and mesoderm
Nanog
Novel
homeodomain
protein
Morula, ICM, epiblast, ES
cells, EC cells, germ cells
Embryonic lethality (E5.5),
lack of epiblast,
differentiation of ICM into
primitive endoderm
Loss of pluripotency,
differentiation into primitive
endoderm
LIF/Stat3-independent
self-renewal,
resistance to retionoic
acid-induced
differentiation
Sox2
SRY-related
HMG box protein
Oocytes, ICM, epiblast,
germ cells, multipotent
cells of extra-embryonic
ectoderm, cells of neural
lineage, brachial arches,
gut endoderm
Embryonic lethal (E6.5),
failure to maintain epiblast
Unknown Unknown
Stat3
Signal
Tranducer and
Activator of
Transcription
family protein
Wide ranges of cell
types
Embryonic lethality
(E6.5-7.5)
Differentiation into
primitive endoderm and
mesoderm (Stat3 signaling
is dispensable in human
ES cells)
LIF-independent
self renewal
Cdx2
Caudal-type
homeodomain
protein
Outer morula cells, TE cell
lineages
Embryonic lethality due to
implantation failure (lack of
functional TE)
Normal contribution to all
cell lineages except TE
and intestinal cells
Differentiation into
trophoblast
Gata6
GATA-binding
protein
Extraembryonic endoderm
lineages
Embryonic lethality (E5.5-
7.5), defects in visceral
endoderm formation
Unknown
Differentiation into
primitive endoderm
Gata4
GATA-binding
protein
Extraembryonic endoderm
lineages
Embryonic lethality (E8-9),
defects in heart
morphogenesis
Can generate cardiac
myocytes, inability to
generate visceral
endoderm and definitive
endoderm of foregut
Differentiation into
primitive endoderm
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cells, ChIP DNA was combined with a microarray platform (ChIP-chip) whereas
for mouse ES cells, the ChIP DNA was linked to concatenated paired-end ditags
and sequenced (ChIP-PET). These studies identified a large number of target
genes and revealed that Oct4, Nanog, and in the case of human ES cells, Sox2
share a substantial portion of their targets.  Further work in mouse ES cells using
ChIP-chip has also been done to identify genomic targets of Oct4 and Nanog,
and this work is described in Chapter 2.  The experiments in this study identify a
different set of targets than the one described by Loh et al (2006), indicating that
each set is a partial representation of the Oct4 and Nanog regulatory network.
This work has, therefore, begun to reveal the circuitry that is responsible for the
combined biological output of these ES cell regulators.
Similarities and Differences Between Mouse and Human ES Cell Genomic
Targets
Oct4, Sox2 and Nanog occupy both transcriptionally active and inactive genes in
mouse and human ES cells.  Active genes include the transcription factors Oct4,
Sox2 and Nanog themselves, as well as others that are highly expressed in ES
cells, such as Rif1, Jarid2 and Smarcad1.  Rif1 has been implicated in regulating
telomere length and might be important for self-renewal (Adams and McLaren
2004).  Although Jarid2 and Smarcad1 have important roles in development
(Schoor, Schuster-Gossler et al. 1993; Jung, Mysliwiec et al. 2005), their
contribution to pluripotency is unknown.  Interestingly, a large portion of the
inactive targets identified in mouse and human ES cells include transcription
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factors involved in lineage-specification (Figure 1(b)).  The developmental
importance of these genes suggests that Oct4, Sox2 and Nanog act in concert to
maintain pluripotency by directly controlling a transcriptional regulatory hierarchy
that specifies differentiation into extra-embryonic lineages in addition to
derivatives of the primary germ layers.
A comparison of Oct4- and Nanog-bound regions identified in these studies,
however, revealed only modest similarity between the target genes in the two
species.  For instance, certain genes such as Hand1 and Myst3 were identified
as targets of Oct4 and Nanog exclusively in human ES cells, whereas others
such as Esrrb were observed only in mouse ES cells.  It is interesting to note that
although Hand1 was not identified as a target in mouse ES cells, its expression
was upregulated upon RNAi-mediated silencing of both Esrrb and Rif1 in these
cells (Loh, Wu et al. 2006).  The lack of orthologous genomic targets could be
due to genuine differences between the gene regulatory networks or a result of
the dissimilarities in genomic platforms used in these studies.  Detailed
comparisons of Oct4, Sox2 and Nanog target genes between the two species will
be imperative for determining the extent to which genetic regulatory information
can be extrapolated from one species to the other.
Although these studies provide an initial framework for deciphering the
mechanisms by which these key regulators elicit their effects, genetic
manipulation of Oct4, Sox2 and Nanog combined with gene expression analyses
is necessary to elucidate which of their targets are important for the maintenance
20
of pluripotency or downstream differentiation events.  Such analyses, reported in
the same study that identified mouse Oct4 and Nanog targets (Loh, Wu et al.
2006), as well as in another study in which mouse ES cells gene expression
patterns were profiled under a wide range of conditions, are critical steps in this
direction (Ivanova, Dobrin et al. 2006).  In addition to confirming a role for Esrrb
in mouse, Ivanova and colleagues recognized Tcl1 and Tbx3 as being important
factors for sustaining an undifferentiated state. Interestingly, Esrrb has been
shown to be important for placental development and germ cell proliferation, and
Tcl1, which is highly expressed in ES cells (Mitsui, Tokuzawa et al. 2003),
enhances cell proliferation and survival through augmentation of PI3K-Akt
signaling (Teitell 2005; Meshorer and Misteli 2006).  Thus, how these factors
contribute to ES cell self-renewal and pluripotency is of particular interest.
Together, these genome-wide studies suggest that Oct4, Sox2 and Nanog form
the basis for a specialized transcriptional regulatory circuitry that allows for
consistent patterning of gene expression during ES cell propagation.
Epigenetic Control of Pluripotency: Chromatin Dynamics and Epigenetic
Profile of Pluripotent ES Cells
Chromatin reorganization is essential for the establishment of new heritable gene
expression programs that accompany lineage specifications (Figure 2)
(Meshorer, Yellajoshula et al. 2006).  For example, ES cell chromatin displays
characteristics of transcriptionally permissive euchromatin, such as an
abundance of acetylated histone modifications and increased accessibility to
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nucleases.  Conversely, lineage specification is typified by a decrease in
acetylation and concomitant increase in heterochromatin formation, indicating
that restriction of developmental potential is associated with a decrease in
genome plasticity.  Recent studies have revealed additional unique properties of
pluripotent chromatin that distinguish these cells from their differentiated
progeny.
An analysis of global chromatin dynamics revealed a highly dynamic association
of structural chromatin proteins (e.g. core and variant histones, the linker histone
H1, and the heterochromatin associated proteins HP1) with the chromatin of
pluripotent cells compared with that of differentiated cell types (Meshorer,
Yellajoshula et al. 2006).  This study also showed that replacement of histone H1
with a version that binds more tightly to chromatin inhibited ES cell differentiation.
These data posit that structural proteins remain loosely associated with
chromatin in pluripotent cells, thereby enabling the reorganization of chromatin
structure during differentiation.
Consistent with the observation that the chromatin of pluripotent nuclei is in an
‘open’ conformation, recent studies have shown that tissue-specific genes that
are expected to be silent in undifferentiated cells might be in a semi-permissive
transcriptional state in ES cells (Szutorisz, Canzonetta et al. 2005; Levings, Zhou
et al. 2006).  For example, active epigenetic marks were noted in ES cells at
discrete sites within the B-cell specific 5-VpreB1 locus prior to gene activation
22
Figure 2.  Epigenetic Characteristics of Pluripotent and Lineage Committed
Cells.  PcG proteins have recently been shown to reversibly silence
developmental regulators in ES cells, a process that might be necessary for the
propagation of an undifferentiated state.  These regulators, which are early
replicating, contain highly conserved non-coding elements (HCNEs), which are
rich in bivalent domains that consist of both H3K27me3 and H3K4me3
modifications.  These domains might provide an epigenetic indexing mechanism
to mark genes for expression at later developmental stages.  During
differentiation of ES cells, the bivalent marks resolve, because early-replicating
genes that are expressed in the lineage-committed cells maintain or acquire
activating H3K4me3 marks, and late-replicating genes that are turned off in these
cells possess repressive H3K27me3 modifications.  Notably, genes that are
weakly induced still possess bivalent domains.
Phc1 
Eed 
Suz12 
Ezh2 
Rnf2 
Bmi Cbx2 
PR C1 
PR C2 
On Weakly Induced Off 
Off 
Early Replicating Late Replicating 
H3K27Me3 
H3K4Me3 
DIFFERENTIATION 
ES CELL 
DEVELOPMENTAL REGULATORS 
Bivalent Domains 
           HCNEs 
 Early Replicating 
LINEAGE COMMITTED CELL 
FIGURE 2.
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during B-cell commitment (Szutorisz, Canzonetta et al. 2005).  Two other reports
(Azuara, Perry et al. 2006; Bernstein, Mikkelsen et al. 2006) support such an
epigenetic indexing mechanism by revealing the existence of dual marks or
‘bivalent’ domains, consisting of repressive histone H3K27me3 and activating
histone H3K4me3 modifications at a large set of developmentally important
genes that are silent in ES cells but activated upon differentiation.  These studies
suggest that lineage-specific genes are cued in ES cells for subsequent
activation during differentiation.  Furthermore, bivalent domains coincide with the
most highly conserved non-coding elements in the mammalian genome,
suggesting an evolutionarily conserved role for these chromatin domains
(Bernstein, Mikkelsen et al. 2006).  The additional observation that Oct4, Nanog
and Sox2 occupied a significant subset of genes that harbor bivalent domains
supports a link between the repressions of developmental regulators and stem
cell pluripotency (Boyer, Lee et al. 2005; Bernstein, Mikkelsen et al. 2006; Boyer,
Plath et al. 2006; Lee, Jenner et al. 2006).  It is important to note that not all
tissue-specific genes appear to contain these bivalent marks and the underlying
chromatin structure at these genes and their contributions to pluripotency await
further characterization.
A Role for Polycomb Group Proteins in Maintaining ES Cell Identity?
Gene expression is influenced by enzymatic activities that can induce both global
and local changes in chromatin structure.  Polycomb group (PcG) proteins were
first identified in Drosophila as transcriptional repressors of homeotic gene
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expression during embryogenesis (Ringrose and Paro 2004).  PcG proteins
comprise at least two distinct repressor complexes (PRC1 and PRC2-PRC3), the
core components of which are highly conserved between fly and human (Levine,
Weiss et al. 2002).  A role for PcG proteins in pluripotency in mammals was
suggested on the basis that PcG components are required for early
developmental gene expression patterning, the early establishment of pluripotent
ES cell lines, and for adult stem cell maintenance.
Recently, the location of PcG components throughout the genome was mapped
in Drosophila (Negre, Hennetin et al. 2006; Schwartz, Kahn et al. 2006; Tolhuis,
Muijrers et al. 2006) and mammals (Boyer, Plath et al. 2006; Bracken, Dietrich et
al. 2006; Lee, Jenner et al. 2006). These studies revealed that in human and
mouse ES cells, the PRC1 and PRC2 complexes bind to a large set of genes
comprised of transcriptional regulators and signaling factors with known roles in
development. Genes occupied by PcG proteins also contained H3K27me3 in
their promoter regions, a repressive histone modification catalyzed by PRC2.
Many of the target genes were de-repressed in the absence of the PRC2
components Eed or Suz12, indicating a direct functional link between PRC2 and
gene silencing in ES cells (Bernstein, Mikkelsen et al. 2006; Boyer, Plath et al.
2006). ES cells lacking Eed can contribute to most cell lineages, suggesting that
PcG proteins are not necessary to maintain pluripotency (Morin-Kensicki, Faust
et al. 2001). However, the observations that Eed mutant ES cells spontaneously
differentiate (Boyer, Plath et al. 2006), and ES cells cannot be derived from
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blastocysts deficient for the PRC2 component Ezh2 (O'Carroll, Erhardt et al.
2001) suggest that PcG proteins are necessary for ES cell identity.
PcG target genes were preferentially activated upon differentiation, indicating
that they are poised for activation in ES cells (Boyer, Plath et al. 2006; Lee,
Jenner et al. 2006). In flies, the maintenance of heritable epigenetic states
requires the interplay between repression mediated by PcG proteins and
activation by Trithorax group (Trx) proteins (Ringrose and Paro 2004). Trx
proteins catalyze lysine 4 tri-methylation on histone H3 (H3K4me3) (Martin and
Zhang 2005). Interestingly, many of the PcG target genes contained bivalent
chromatin domains in their promoter regions (Azuara, Perry et al. 2006;
Bernstein, Mikkelsen et al. 2006; Boyer, Plath et al. 2006; Lee, Jenner et al.
2006), consistent with the idea that chromatin accessibility is governed by the
balance between positively and negatively acting factors (Dillon and Festenstein
2002). Additionally, PcG target genes are replicated early in ES cells, a property
associated with transcriptionally active euchromatin (Perry, Sauer et al. 2004;
Azuara, Perry et al. 2006). However, replication timing was not significantly
altered in Eed mutant ES cells (Szutorisz, Canzonetta et al. 2005) suggesting
that the presence of H3K4me3 or additional factors was required to maintain
these genes in a semi-permissive transcriptional state. Many PcG target genes
were also bound by Oct4, Sox2, and Nanog, indicating that these ES cell
regulators may play a role in recruiting PcG complexes to catalyze the silencing
of these genetic loci (Boyer, Plath et al. 2006; Lee, Jenner et al. 2006). The
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identity of the components that catalyze the addition of the activating mark at
these genes in ES cells, as well as identification of the factors that recruit PcG
and Trx proteins will be important to better understand how these genes are
regulated. A recent study also revealed a role for Mbd3, an essential component
of the Nucleosome Remodeling and Histone Deacetylation (NuRD) complex, in
ES cell differentiation (Kaji, Caballero et al. 2006). In C. elegans, germline-
specific chromatin states specified through PcG-like activities are reorganized in
somatic cells by a NuRD-like activity (Shin and Mello 2003). Thus, it is likely that
the balance between pluripotency and lineage commitment is dependent upon
the correct spatial and temporal expression of genes orchestrated by the action
of both genetic and epigenetic factors.
(II) REPROGRAMMING TO A PLURIPOTENT STATE
Restriction of Developmental Potency & The Need for Nuclear
Reprogramming
The promise that ES cells hold for therapeutic purposes has been countered with
a number of practical and ethical dilemmas, since the production of these cells
involves the destruction of embryos.  Reprogramming somatic cells into an ES
cell-like state would be a suitable alternative to circumvent these issues.  The
interest in reprogramming dates back to the 1950s, when Briggs and King
showed through somatic cell nuclear transfer experiments in frog (Rana pipiens)
embryos, a progressive loss of nuclear potency with increasing developmental
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age (King and Briggs 1956).  They isolated donor nuclei from cells at different
stages of development, and transferred them into enucleated oocytes to examine
the developmental potency of these nuclei.  Their results showed that even
though most nuclei from blastula cells could generate tadpoles, there was a
substantial decrease in the ability of nuclei from later stages of development,
such as gastrula and neurula, to produce offspring.  Therefore, these
observations were consistent with the notion that even though the genetic
material of cells at different developmental stages is equivalent, genomic
modifications restrict the nuclear potency of these cells as they undergo
differentiation.  However, the cloning of mammals such as Dolly has shown that
even the potential of differentiated cell nuclei can be altered (Wilmut, Schnieke et
al. 1997).  Therefore, these modifications to the genome are reversible, even
though the reprogramming process is extremely inefficient.  The road to
reprogramming has been one with major challenges, and some of the strategies
that have been employed to overcome these hurdles are discussed here.
Strategies for Reprogramming to a Pluripotent State
(i) Nuclear Transfer
As described earlier, Somatic Cell Nuclear Transfer (SCNT) or Nuclear Transfer
(NT) was the first method employed to reprogram the genome of a differentiated
cell into a pluripotent one.  Such a technique allows for the derivation of patient-
specific ES cell lines, which have the potential to be used for therapeutic
purposes.  The process of nuclear cloning was successfully accomplished in
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mammals, when the sheep Dolly was cloned by transplanting the nucleus of a
differentiated mammary epithelium cell into an enucleated oocyte (Wilmut,
Schnieke et al. 1997).  Subsequently, this technique has also been used to clone
other mammals, such as cattle (Kato, Tani et al. 1998), goats (Baguisi, Behboodi
et al. 1999), pigs (Onishi, Iwamoto et al. 2000; Polejaeva, Chen et al. 2000) and
mice (Wakayama, Perry et al. 1998).  Moreover, generation of monoclonal mice
by NT from mature lymphocytes (Hochedlinger and Jaenisch 2002), as well as
the cloning of mice from post-mitotic olfactory neurons indicated that even the
nuclei of terminally differentiated cells can be coaxed to re-enter the cell cycle
and be reprogrammed to a totipotent state (Eggan, Baldwin et al. 2004).  A proof-
of-principle experiment in mice showed that disease-specific ES cells derived
from NT blastocysts could be repaired by homologous recombination and used to
treat an immunological disorder (Rideout, Hochedlinger et al. 2002).
In order to get around the issue of embryo destruction for ES cell derivation,
William Hurlbut, a member of the United States President’s Council on Bioethics,
suggested a possible solution called Altered Nuclear Transfer (ANT) (Hurlbut
2005).    This procedure was proposed as a variation on NT, since it would
generate abnormal embryos that would fail to implant in the uterus and not
develop into viable offspring.  Such a technique was accomplished by disrupting
the gene Cdx2, which is crucial for differentiation into the trophectodermal
lineage (Meissner and Jaenisch 2006).  Mouse embryos lacking this gene are
unable to develop beyond the blastocyst stage since they do not form placentas
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and cannot implant in the uterus.  However, the blastocysts of these embryos
have an ICM, which can be explanted in tissue culture to give rise to pluripotent
ES cells (Chawengsaksophak, de Graaff et al. 2004; Strumpf, Mao et al. 2005).
Despite this success with NT, the major challenges plaguing this technology are
that it is an extremely inefficient process, and a large number of cloned offspring
have epigenetic instability that leads to abnormal gene expression and
organismal growth (Humpherys, Eggan et al. 2002; Blelloch, Wang et al. 2006).
A large number of cloned embryos die during gestation, exhibiting characteristics
of large offspring syndrome (Young, Sinclair et al. 1998; Chavatte-Palmer,
Heyman et al. 2000), frequently with respiratory and metabolic problems, and
large and abnormal placentas (Hill, Roussel et al. 1999; Wakayama and
Yanagimachi 1999; Hill, Burghardt et al. 2000).  Therefore, even though patient-
specific ES cells may be derived by reprogramming a somatic cell through NT,
these cells are likely to have epigenetic abnormalities that could pose potential
issues for therapeutic uses.
(ii) Reprogramming by Fusion
Another approach to reprogram somatic cells into a pluripotent state has been to
fuse them with ES cells, thereby creating hybrids in which the differentiated
nuclei get epigenetically reprogrammed and exhibit properties of ES cells.  This
technique has been demonstrated successfully in mice, where adult thymocytes
were fused to ES cells, and the resulting hybrids could contribute to all three
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germ layers, revealing the pluripotent features of the parent ES cells (Tada,
Takahama et al. 2001).  Another indication of reprogramming in these hybrids
was that the inactive somatic X chromosome and repressed pluripotency
markers, such as Oct4, were reactivated upon fusion with ES cells.
Reprogramming through fusion has also been accomplished in human cells,
where human fibroblasts as well as myeloid progenitors were reprogrammed by
fusion with human ES cells (Cowan, Atienza et al. 2005; Yu, Vodyanik et al.
2006).
The key issue with using this cell fusion approach is the generation of tetraploid
hybrid cells.  If these reprogrammed hybrids are to be used for therapeutic
purposes, it will be necessary to eliminate the ES cell genome used for the fusion
procedure.  Although the targeted elimination of a few chromosomes in these
hybrid cells has been accomplished with the use of a chromosomal deletion
cassette (CEC), this method of obtaining diploid reprogrammed cells poses major
risks of creating genomic instability that would hamper cell-survival (Matsumura,
Tada et al. 2007).
(iii) In Vitro Reprogramming with Defined Transcription Factors
A major feat in the field of reprogramming was accomplished in a recent study,
where four transcription factors were used to reprogram somatic cells into an ES
cell-like state (Takahashi and Yamanaka 2006).  In this experiment, mouse
embryonic fibroblasts (MEFs), as well as adult tail-tip fibroblasts were infected
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with viruses carrying transgenes of the transcription factors Oct4, Sox2, C-myc
and Klf4.  The infected fibroblasts were selected for the activation of Fbx15,
which is a direct target of Oct4 (Tokuzawa, Kaiho et al. 2003).  Although Fbx15 is
expressed predominantly in ES cells, it seems to be dispensable for the
maintenance of pluripotency and mouse embryonic development.  Infected cells
in which Fbx15 had been activated were known as Fbx15-iPS (induced
pluripotent stem) cells.  These cells were shown to be pluripotent since they
could form teratomas.  However, they were unable to generate any live chimeras.
Therefore, these Fbx15-iPS cells are thought to represent a partial state in
reprogramming.
In subsequent studies, the activation of endogenous Oct4 or Nanog loci was
used as a selection criterion for reprogramming.  The Oct4- and Nanog-iPS cells
obtained in these studies were completely reprogrammed, since not only could
they give rise to teratomas, they could also generate live germline chimeras
(Maherali, Sridharan et al. 2007; Okita, Ichisaka et al. 2007; Wernig, Meissner et
al. 2007).  Moreover, in contrast to the partially reprogrammed Fbx15-iPS cells,
the Oct4- and Nanog-neo iPS cells had completely reprogrammed, unmethylated
endogenous Oct4 and Nanog promoters. Additionally, the inactive somatic X
chromosome was also activated in the Oct4- and Nanog-iPS cells (Maherali,
Sridharan et al. 2007).   Further work on these cells has also shown that the
pluripotency markers, Alkaline Phosphatase (AP), Stage-specific embryonic
antigen 1 (SSEA1), Oct4 and Nanog get activated during the course of
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reprogramming (Wernig, Meissner et al. 2007; Brambrink, Foreman et al. 2008;
Stadtfeld, Maherali et al. 2008).  However, the major difference between the
studies using Fbx15 and Oct4 or Nanog as selection markers for reprogramming
was the time at which selection was started.  In the first study, selection was
started early (day 3 post infection) in order to obtain Fbx15-iPS cells, whereas in
the case of Oct4 and Nanog-iPS cells, selection was started at later times (days
6 or 9 post infection).  Therefore, it is still unclear whether the partial
reprogramming in the former case is obtained due to the fact that Fbx15 is not
relevant to pluripotency, or because of the difference in selection timing.  This
issue is addressed in further detail in Chapter 3 in an effort to shed more light
onto the mechanisms by which a somatic cell can get reprogrammed partially or
completely into a pluripotent state.
Mechanism of Reprogramming Fibroblasts into iPS Cells
Recent studies have started to explore the mechanisms by which a somatic cell
can be reprogrammed in vitro into iPS cells by viral-mediated transduction of
Oct4, Sox2, Klf4 and c-Myc transgenes (Brambrink, Foreman et al. 2008;
Stadtfeld, Maherali et al. 2008).  This work has been focused on defining the
steps of reprogramming by determining the kinetics of pluripotency marker
expression during this process (Figure 3).  Both groups observed that the
activation of such markers was a gradual and sequential process, and not a
stochastic one.  FACS analyses of cells isolated at different time points after
infection with the four factors, revealed that the pluripotency marker, AP was the
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first one to be reactivated.  This was followed by the upregulation of the cell
surface marker SSEA1, which is expressed in pluripotent cells, and a
concomitant downregulation of Thy1, a cell surface antigen expressed in
fibroblasts and differentiated cells (Rege and Hagood 2006).  The pluripotency
genes, Oct4, Nanog and Sox2 were upregulated later in the reprogramming
process, and were accompanied by the reactivation of telomerase (mTert), as
well as the silent X chromosome.  Nearly all cells expressing Oct4 or Nanog also
expressed the early markers, AP and SSEA1, but the reverse was not true for
most AP and SSEA1 positive cells isolated at early time points.  This observation
supported the notion that the reactivation of pluripotency genes is a gradual and
sequential process, and that SSEA1 marks an intermediate step in
reprogramming. It will be of interest in the future to determine whether the
occurrence of late events, such as Oct4 and Nanog expression is dependent on
the early events in this process.
These studies also examined the minimal time of transgene expression that was
required for reprogramming (Brambrink, Foreman et al. 2008; Stadtfeld, Maherali
et al. 2008).  In order to address this question, the four transcription factors were
expressed using doxycycline-dependent inducible viruses carrying transgenes for
these factors.  Doxycycline was added to the fibroblasts immediately after they
were infected with these viruses, and it was withdrawn at different time points
after infection.  The results of these studies suggested that transgene expression
was required at least up to days 12-16 in order to obtain fully reprogrammed iPS
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colonies (Figure 3).  If Doxycycline was withdrawn earlier, then cells in the
reprogramming process would revert to a fibroblast-like morphology.  Both
groups also noted that after stable iPS cells were obtained, downregulation of
transgene expression was required in order for iPS cells to differentiate.
An interesting observation made by several groups has been that depending on
the timing of selection for pluripotency markers, drug resistant colonies appear at
a wide range of time points following infection with the four factors (Maherali,
Sridharan et al. 2007; Okita, Ichisaka et al. 2007; Wernig, Meissner et al. 2007;
Brambrink, Foreman et al. 2008; Stadtfeld, Maherali et al. 2008).  However, in a
number of drug resistant colonies that are obtained early, the endogenous Oct4
and Nanog loci do not seem to be reactivated.  This discrepancy between the
timing of drug resistance and reactivation of pluripotency genes is not well
understood.  One possible explanation for this observation could be that in such
cells, a low level of Oct4 or Nanog expression may be present, which is sufficient
to confer drug-resistance, but not enough for complete reprogramming, thereby
supporting the idea that this is a process in which pluripotency genes are
gradually reactivated.
Applications of iPS cells in Therapeutic Medicine
The iPS cells obtained by viral transduction of the four transcription factors are
morphologically and functionally indistinguishable from ES cells.  Similar to ES
cells, these iPS cells also hold great therapeutic potential, while circumventing
the ethical dilemmas associated with ES derivation.  In a recent proof-of-principle
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Figure 3.  Sequence of marker expression during reprogramming.  Kinetics
of fibroblast and pluripotency marker expression is represented by the
rectangular gradients.  The minimal amount of time for which transgenes
expressing the four factors must be expressed for complete reprogramming, is
also shown.
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study, iPS cells generated from murine fibroblasts were used to successfully treat
a mouse model of sickle-cell anemia (Hanna, Wernig et al. 2007).  Furthermore,
iPS cells could also be used to derive functional neuronal cell types in vitro,
which when transplanted into the brain of a rat model of Parkinson’s disease,
could alleviate some symptoms associated with this disorder (Wernig, Zhao et al.
2008).
Even though this same combination of four transcription factors can be used to
obtain iPS cells from human fibroblasts (Takahashi, Tanabe et al. 2007; Yu,
Vodyanik et al. 2007; Park, Zhao et al. 2008), there are several issues that must
be dealt with before such iPS cells can be used for medical purposes.  The
generation of iPS cells has thus far relied on virus-mediated transduction of the
four transcription factors, as well as on drug-selection for the activation of Fbx15,
Oct4 or Nanog markers.  The use of viruses and drugs could potentially affect the
eventual application of these cells in human therapies, and suitable alternatives
for these experimental requirements need to be explored.  The issue of drug
selection has been addressed in a recent study, where completely
reprogrammed, genetically unmodified iPS cells were obtained without drug
selection, based solely on morphological similarity to ES cells (Meissner, Wernig
et al. 2007).  An additional problem with using these four factors for
reprogramming is that iPS cell derived mice frequently develop tumors (Okita,
Ichisaka et al. 2007).  In an effort to address this issue, iPS cells were derived
without the c-myc oncogene.  Although reprogramming in this case was
39
significantly slower and less efficient, mice derived from these cells did not have
c-myc-induced tumors (Nakagawa, Koyanagi et al. 2008; Wernig, Meissner et al.
2008).  It is still unclear whether the introduction of the other three transcription
factors will induce tumors at later stages of development.  If this is the case, then
safer substitutes for these reprogramming factors will have to be explored.  Much
of the current research in reprogramming is aimed at addressing these issues, in
the hope that medical and scientific benefits will be reaped from this work,
unhindered by the ethical and practical dilemmas that currently swamp this field.
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ABSTRACT
Genome-wide approaches have begun to reveal the transcriptional networks
responsible for pluripotency in embryonic stem (ES) cells.  Chromatin
Immunoprecipitation (ChIP) followed either by hybridization to a microarray
platform (ChIP-chip) or by DNA sequencing (ChIP-PET), has identified binding
targets of the ES cell transcription factors Oct4 and Nanog in humans and mice,
respectively. These studies have provided an outline of the transcriptional
framework involved in maintaining pluripotency.  Recent evidence with
comparing multiple technologies suggests that expanding these datasets using
different platforms would be a useful resource for examining the mechanisms
underlying pluripotency regulation.  We have now identified Oct4 and Nanog
genomic targets in mouse ES cells by ChIP-chip and provided the means to
compare these data with previously reported ChIP-PET results in mouse ES
cells. We have mapped the sequences of Oct4 and Nanog binding events from
each data set to genomic coordinates, providing a valuable resource to facilitate
a better understanding of the ES cell regulatory circuitry.  Interestingly, although
considerable differences are observed in Oct4 and Nanog occupancy as
identified by each method, a substantial number of targets in both data sets are
enriched for genes with known roles in cell-fate specification and are differentially
expressed upon Oct4 or Nanog knockdown.  This study suggests that each data
set is a partial representation of the overall ES cell regulatory circuitry, and
through integrating binding data obtained by ChIP-chip and ChIP-PET, the
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methods presented here provide a useful means for integrating datasets
obtained by different techniques in the future.
INTRODUCTION
Embryonic stem (ES) cells are derived from the inner cell mass (ICM) of the
embryo and possess the property of pluripotency, which is the ability to develop
into any cell lineage of the organism (Evans and Kaufman 1981; Martin 1981;
Thomson, Itskovitz-Eldor et al. 1998).  The derivation of these cells has had
significant impact on biomedical research and has important implications for
regenerative medicine.  Consequently, a detailed knowledge of the mechanisms
governing pluripotency in ES cells is necessary to realize the potential of these
cells.  The homeodomain transcription factors Oct4 and Nanog are uniquely
expressed in pluripotent cell types and have essential roles during development
(Boyer, Mathur et al. 2006; Niwa 2007). For instance, Oct4 knockout embryos
and ES cells differentiate into trophectoderm, whereas overexpression of the
gene leads to differentiation into primitive endoderm and mesoderm lineages
(Nichols, Zevnik et al. 1998; Niwa, Miyazaki et al. 2000).   Loss of Nanog in the
early embryo and ES cells results in differentiation into primitive endoderm
(Chambers, Colby et al. 2003; Mitsui, Tokuzawa et al. 2003).  Conversely, Nanog
over-expression obviates the need for the cytokine, leukemia inhibitory factor
(LIF) in ES cell self-renewal(Chambers, Colby et al. 2003; Mitsui, Tokuzawa et al.
2003).  Collectively, these studies suggest that Oct4 and Nanog function in
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concert to regulate pluripotency in the early embryo, and similarly in ES cells to
govern the transcriptional regulatory circuitry.
Recent genomic studies in ES cells have provided the foundation for
understanding the genetic network that is the collective output of these
pluripotency factors.  Studies in both human and mouse ES cells have used
Chromatin Immunoprecipitation (ChIP) combined with genome-wide technologies
to uncover Oct4 and Nanog genomic binding events that may underlie
transcriptional regulatory circuitries involved in maintaining a stem cell state
(Boyer, Lee et al. 2005; Loh, Wu et al. 2006; Kim, Chu et al. 2008).  Such
investigations have shown that in both species, Oct4 and Nanog occupy a large
number of transcriptionally active and silent genes, many of which are
transcriptional regulators that have been implicated in lineage specification and
cell fate determination.  Moreover, a substantial overlap between the Oct4 and
Nanog genomic targets exists within each data set, suggesting that these two
factors act in concert to regulate a common set of downstream pathways. This
has been further substantiated by gene-expression studies following shRNA-
mediated knockdown of Oct4 and Nanog (Ivanova, Dobrin et al. 2006).
ChIP coupled with a genome-wide DNA detection platform has been useful in
studying protein-DNA interactions.  The data obtained from these different
platforms, however, are expected to exhibit variations due to the technical
differences in the methods, as well as in data analysis. To date, ES cell binding
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data have been collected using ChIP-PET (Paired End Ditags) (Loh, Wu et al.
2006) and ChIP-chip (Kim, Chu et al. 2008) for mouse ES cells and ChIP-chip for
human ES cells (Boyer, Lee et al. 2005).  However, comprehensive technological
comparisons between ChIP-chip and ChIP-PET indicate that composite data sets
that incorporate information from multiple platforms in a complementary fashion
will be most useful in examining these networks in a comprehensive manner
(Euskirchen, Rozowsky et al. 2007).  Such analysis is necessary since the
binding data obtained from different platforms can vary due to the differences in
sample processing for each method.  In the study by Kim et al (Kim, Chu et al.
2008), the authors provide a comparison between Oct4 and Nanog targets
obtained from ChIP-chip and previously reported ChIP-PET data (Loh, Wu et al.
2006).  However, such overlap can vary dramatically depending on the
thresholds used for determining bound regions by each experimental method.
Since these thresholds are to a large extent, arbitrary, it is important to examine
how the binding data obtained by different platforms change under a wide range
of threshold values.
To this end, we have employed ChIP-chip to identify the genomic binding targets
of the pluripotency factors Oct4 and Nanog in mouse ES cells.  Additionally, we
have devised methods to examine these results along with previously published
data for these factors using ChIP-PET under a wide range of binding thresholds
(Loh, Wu et al. 2006).  All data have been re-mapped to the same version of the
mouse genome, and provide a resource for studying this expanded
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transcriptional network obtained by integrating our ChIP-chip data and previously
reported ChIP-PET results.  Our analyses revealed substantially different sets of
Oct4 and Nanog targets identified by each technique. However, a significant
proportion of these targets included genes encoding transcription factors and
other regulators of development in both data sets. Interestingly, many of the
genes identified in both studies were differentially expressed upon Oct4 or Nanog
knockdown in ES cells, suggesting that these targets were regulated by Oct4 and
Nanog.  Importantly, an examination of multiple data sources provided in this
study has revealed a more comprehensive framework for understanding the
mouse ES cell regulatory network.
RESULTS
Oct4 and Nanog ChIP-Chip Binding Data
DNA sequences occupied by Oct4 and Nanog in mouse ES cells were identified
in three independent biological replicates using ChIP as previously described
(Boyer, Lee et al. 2005). Samples were hybridized to microarrays that contained
oligonucleotide probes that span the region –4 to +4 kb relative to the
transcriptional start sites (TSSs) for 19,993 annotated mouse genes and 258
miRNAs (see supplementary notes).  Based on previously established criteria,
bound regions were identified as peaks of ChIP-enriched DNA that span closely
neighboring probes (Figure 1a, b, c, d; see supplementary note) (Boyer, Lee et
al. 2005).  Moreover, only those regions that were bound in all three replicates
are represented in the final data set.  Using these stringent parameters, we
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Figure 1.  Illustrative examples of ChIP-enrichment ratios of Oct4 (a, b, e) and
Nanog (c, d, f) bound regions obtained from ChIP-Chip experiments with
promoter arrays (a-d) and chromosome 19 arrays (e. f). The chromosomal
position of the genes, as well as the genomic scale is represented along the x-
axis. The fold enrichment of the probes is shown on the y-axis. These enrichment
ratios represented the medians of the per-pixel ratios scanned at each spot on
the microarray. Exons and introns are represented by boxes and horizontal lines,
respectively. The transcription start site and direction of transcription are denoted
by arrows.  (g)  Venn diagram depicting the overlap between gene whose
promoters were bound by both Oct4 and Nanog in ChIP-Chip experiments (p-
value< 0.001).
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identified 1351 (6.8%) and 1124 (5.6%) known protein-coding genes (Table S1)
and 22 (8.5%) and 23 (8.9%) microRNA genes (Table S2) that are occupied by
Oct4 and Nanog respectively.
Several lines of evidence indicated that this ChIP-chip data set is of high quality.
First, in accordance with previous findings in both mouse and human ES cells
(Boyer, Lee et al. 2005; Loh, Wu et al. 2006), gene ontology (GO) analyses
revealed that a significant number of promoters occupied by Oct4 and Nanog
contained transcription factors and genes involved in developmental processes
(Table S3).  Some of these genes, such as Jarid2, Cdx2 and Sox2 have been
identified previously as Oct4 or Nanog targets (Loh, Wu et al. 2006).
Additionally, as seen in both the human and mouse ES cell studies, Oct4 and
Nanog bind to their own as well as each other’s promoters (Boyer, Lee et al.
2005; Chew, Loh et al. 2005; Rodda, Chew et al. 2005; Loh, Wu et al. 2006).  We
also observed a substantial overlap between the Oct4 and Nanog-bound genes,
where 373 gene promoters were occupied by both these factors (Figure 1g).
Together, these binding data support prior models suggesting that Oct4 and
Nanog act together to maintain ES cell pluripotency by promoting self-renewal
and by regulating a number of developmentally important genes.
Given that it has been reported that a significant number of binding sites may be
located outside of promoter regions (Loh et al., 2006), we next hybridized the
Oct4 and Nanog ChIP samples to chromosome arrays that tiled the entire non-
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repeat portion of mouse chromosome 19 (see supplementary note). Binding
events were analyzed similarly to the promoter arrays and occupied regions were
identified using the same criteria (Table S4).   In addition to promoter regions
bound by Oct4 and Nanog, this analysis revealed Oct4 and Nanog binding sites
that were undetectable on the promoter arrays (Figure 1 e and f).  Bound regions
were classifed in relation to the nearest gene within 100 kb as: 5’ proximal (0-10
kb upstream), 5’ distal (10-100 kb upstream), 3’ proximal (0-10 kb downstream),
3’ distal (10-100 kb downstream) and intragenic (within the gene).  Sites that
were located >100 kb away from the nearest gene were classified as gene desert
regions. 208 binding events for Oct4 and 381 for Nanog were identified using the
chromosome array.  For both factors we observed similar trends in distribution of
these binding sites across chromosome 19 (Figure 2).  Among Oct4 targets,
38.9% of the sites were in intragenic, 7.7% in the 3’ proximal, 17.8% in the 3’
distal, 7.2% in 5’ proximal, 12.5% in 5’ distal, and 15.9% in gene desert regions.
Following a similar distribution, the Nanog data showed 40.9% of the binding
sites in intragenic, 7.3% in the 3’ proximal, 15.2% in the 3’ distal, 7.1% in 5’
proximal, 14.2% in 5’ distal, and 15.2% in gene desert regions. These results
show that Oct4 and Nanog targets are located across different genomic regions,
and such extensively tiled arrays can be used to obtain more detailed binding
data on a genome-wide scale.  Additionally, the finding that approximately 40%
of the binding sites were found in intragenic regions is also in concordance with
earlier observations made in the ChIP-PET study for both Oct4 and Nanog,
63
Figure 2.  Genomic distribution of (a) Oct4 and (b) Nanog binding sites on
mouse chromosome 19, obtained by ChIP-chip analyses.
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indicating that the Chromosome 19 array results are representative of the binding
distribution in the genome.
Oct4 and Nanog ChIP-PET Data
In order to compare genomic targets across different platforms, we re-analyzed
previously reported ChIP-PET experimental data for Oct4 and Nanog (Loh, Wu et
al. 2006).  In the ChIP-PET method, immuno-enriched DNA fragments are cloned
into a plasmid library, which is then transformed into one containing
concatenated signature paired-end ditag sequences.  The DNA fragments or
binding sites are subsequently sequenced and the reads are mapped to the
mouse genome.  All binding sites were first classified relative to the nearest gene
(as intragenic, 5’ distal, 5’ proximal, 3’ distal, 3’ proximal and gene desert
regions), according to the criteria described earlier. Next, we performed GO
analyses on the ChIP-PET targets in each of these regions.  As summarized in
Table S3, we observed that similar to ChIP-chip data, both Oct4 and Nanog
binding targets had a significant representation of genes encoding transcription
factors and regulators of cell fate.
In order to analyze the ChIP-PET and ChIP-Chip data together, all raw ChIP-PET
sequence reads were re-mapped to the same version of the mouse genome
(mm6) used in the ChIP-chip experiments.  The sequence reads were between
34-36 bp, and only those that had at least 34 matched base pairs and a gap-
length of 10 bp were considered to be uniquely mapped to the mouse mm6
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genome.  Out of 951,437 Oct4 reads, 198,802 (20.9%) could be uniquely
mapped. Similarly, among 624,237 Nanog reads, 333,248 reads (53.4%) could
be mapped uniquely to the genome. Importantly, the methods and criteria used
to remap data to a different genome version will provide a useful resource for
performing such analyses with other sequencing based platforms that use other
genome versions.
In ChIP-PET experiments, a minimum number of overlapping sequence reads
was used as a criterion for identifying binding events.  A region was considered
occupied by Oct4 and Nanog if it had at least 4 or 3 overlapping sequence reads,
respectively. In order to analyze our ChIP-chip findings in relation to these data,
we examined only those ChIP-PET reads that had corresponding regions
represented on the mouse promoter arrays (576 for Oct4 and 924 for Nanog).
Additionally, for Chromosome 19, 90 Oct4 targets and 224 Nanog targets could
be remapped for the ChIP-PET data.
Examination of ChIP-chip and ChIP-PET Bound Regions
To examine the binding events obtained by ChIP-chip and ChIP-PET, we used
the ‘Genomic Spatial Events’ (GSE) Visualizer program (Danford TW 2007)
(Figure 3, see also Supplementary Note). GSE is a Java software package,
written to allow interactive browsing of ChIP-chip and ChIP-PET data, and
genome annotations, from a remote database over a network connection
(software for this program is available upon request).  It handles datasets that are
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Figure 3.  GSE Spatial Visualizer snapshots showing illustrative examples of
ChIP-Chip and ChIP-PET data for (A) Oct4 and (B) Nanog.  The fold enrichment
for a single ChIP-Chip replicate (for Oct4 or Nanog) is shown against the
genomic coordinate scale for the gene (in base pairs).  The grey boxes represent
the locations of 'bound regions' from each of the factor's three ChIP-Chip
replicates.  The white boxes show the overlapping ChIP-PET reads for the
displayed region.  A ‘bound region’ in ChIP-PET experiments had 4 or more
overlapping reads in Oct4, and 3 or more overlapping reads in the case of
Nanog. Gene exons and introns are represented by pink boxes and solid
horizontal lines respectively.  For each visualized gene, the transcriptional start
site, direction of transcription and RefSeq annotation derived from the UCSC
database are also specified.
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simultaneously mapped against multiple genome builds, a requirement for any
system that is to compare new experimental data against older datasets. The
software is built to run on multiple platforms, and also provides a software
interface for custom-written analysis modules.  The locations of bound probes
from replicate ChIP-chip experiments, as well as the overlapping ChIP-PET
reads for the respective regions could be simultaneously visualized using the
program.  Therefore, this tool provides an important resource to compare data
from multiple sources at a variety of genomic scales.  It can also be utilized in the
future for such purposes as data using other technologies become available for
expanding the ES cell transcriptional circuitry.
In order to determine how the analysis methods and threshold criteria in ChIP-
chip and Chip-PET experiments influenced the overall concordance between
data sets, we examined the data by generating ‘Recovery Curves’ (see methods;
Figures 4 and 5).  A binding event in one experiment was considered ‘recovered’
by (or overlapping with) a similar event in a second experimental type if both
events were within a fixed genomic distance (recovery distance) from each other.
A typical p-value threshold of 0.001 was used initially to determine significant
binding events in ChIP-chip experiments, and a minimum number of ‘overlapping
sequence reads’ was used to establish bound regions in ChIP-PET experiments
(4 or more overlapping reads for Oct4 targets, and 3 or more overlapping reads
for Nanog).  We generated two types of Recovery curves to analyze the ChIP-
chip and ChIP-PET data.  The ChIP-PET Recovery curve examined the fraction
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of ChIP-PET regions overlapping with the ChIP-chip data at a wide range of p-
value thresholds for the ChIP-chip experiments. In this instance, the threshold
criteria were kept constant for the ChIP-PET experiments, and the ChIP-PET
recovery (y-axis) was plotted against a range of ChIP-chip p-values (x-axis).
Conversely, the other type of curve represented the ChIP-chip recovery at
varying ChIP-PET ‘overlapping read’ threshold values. The ChIP-chip p-value
threshold was kept constant at 0.001, and the ChIP-chip recovery (y-axis) was
examined at different numbers of ChIP-PET sequence reads (x-axis).  We
examined each type of curve under a range of recovery distances, as binding
events identified by both methods may not have exact overlaps due to
differences in sample processing and technologies.
Not surprisingly, we observed that the recoveries of Oct4 and Nanog targets
obtained by one experimental method increased as the threshold value for the
other method was relaxed. The recoveries also increased as the distance
permitted between a ChIP-chip peak and corresponding ChIP-PET peak was
increased (Figures 4).  As an example of these results, converting the recoveries
into percentages, among Oct4-bound regions, 24% of the peaks identified by
ChIP-PET (>4 reads) were recovered in the ChIP-Chip data (p-value<0.001)
within a distance of 1 kb.  Conversely, using the same thresholds, 9.3% of the
Oct4-bound peaks found by ChIP-chip were recovered in the ChIP-PET data.
(Table S5).  From the Nanog data we observed that 28.1% of the ChIP-PET
peaks (>3 reads) were recovered in ChIP-chip bound regions (p-value<0.001)
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Figure 4. Oct4 and Nanog Promoter Array Recovery Curves.  (A) and (C)
show the Oct4 and Nanog ChIP-PET recovery curves respectively for the
promoter arrays.  These represent the fraction of ChIP-PET recovery under a
range of ChIP-Chip p-value cut-offs.  (B) and (D) are Oct4 and Nanog ChIP-chip
recovery curves respectively. These show the ChIP-Chip percent recovery at
varying ChIP-PET read thresholds.  In all cases, recovery curves are made for a
variety of distances (0-8 kb) permitted between a ChIP-PET peak and ChIP-PET
read for them to be considered ‘overlapping’.
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Figure 5. Oct4 and Nanog Chromosome Array Recovery Curves.  (A) and (C)
show the Oct4 and Nanog ChIP-PET recovery curves respectively for the
chromosome array.  These represent the fraction of ChIP-PET recovery under a
range of ChIP-Chip p-value cut-offs.  (B) and (D) are Oct4 and Nanog ChIP-chip
recovery curves respectively. These show the ChIP-Chip percent recovery at
varying ChIP-PET read thresholds.  In all cases, recovery curves are made for a
variety of distances (0-8 kb) permitted between a ChIP-PET peak and ChIP-PET
read for them to be considered ‘overlapping’.
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within a 1 kb area.  Conversely, the ChIP-Chip percent recovery from ChIP-PET
bound regions (>3 reads) was 19.5% (Table S6).  Therefore, these recovery
curves illustrated the importance of recovery distance and threshold calibration in
examining data from different sources.
Similar analyses were performed using the mouse chromosome 19 data and
corresponding ChIP-PET regions. We noted that the amount of overlap between
ChIP-PET and ChIP-chip increased with the more extensively tiled arrays (Figure
5). This is because many targets identified in ChIP-PET experiments would not
be identified by the promoter arrays, since regions outside of the promoter were
not represented on these arrays. In summary, the Oct4 and Nanog ChIP-chip
and ChIP-PET data sets show that the recovery among datasets varies as any of
the threshold criteria for binding events are altered.  Further evaluation of the
binding events identified through both techniques, by genetic manipulation of the
corresponding genes in ES cells, will lend better insight into the genes
responsible for maintaining pluripotency.
Previous reports have suggested that a lack of concordance between array- and
sequencing based technologies may also be due to the repeat-masking feature
of tiled microarrays as well as a sequencing depth issue with ChIP-PET
(Euskirchen, Rozowsky et al. 2007; Kim, Chu et al. 2008).  Since 99% of the
ChIP-chip probes on our promoter arrays do not have any major overlaps with
repeat regions, and only 8.1% of all ChIP-PET sequences fall in repeat-masked
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regions, we do not expect the results of this study to change by any significant
degree if this small fraction of ChIP-PET sequences is removed from the
analysis.  In order to further examine the sequencing depth issue, the ChIP-Chip
and ChIP-PET data on Chromosome 19 was used to performed a sequence-
depth analysis to examine the changes in ChIP-chip recovery as increasing
number of ChIP-PET sequences are randomly sampled (Figure S3 and Table
S10).  According to our observations for both Oct4 and Nanog, the number of
ChIP-chip targets recovered increased with the number of ChIP-PET reads
sampled, and did not approach a saturation point, even when all ChIP-PET reads
for chromosome 19 were sampled.  This result suggests that the lack of recovery
of ChIP-chip targets in the ChIP-PET data can, at least in part, be explained by a
lack of depth in sequencing.
Differentially Regulated Targets of OCT4 and NANOG
Since protein-DNA binding alone is not indicative of a regulatory event, the
expression of Oct4 and Nanog binding targets obtained through ChIP-chip and
ChIP-PET was compared by comparing binding data with previously published
Oct4 and Nanog RNAi gene expression profiles in ES cells (Loh, Wu et al. 2006).
The expression levels of targets determined exclusively by either technique, and
those overlapping in both were examined in Oct4 or Nanog knockdown ES cells
(as summarized in Table 1.  See also Tables S7 and S8 and supplementary
note).   We found that among the Oct4-bound targets (with corresponding
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Table 1. Differential expression of Oct4 and Nanog targets in RNAi experiments.
Method for
determining bound
targets
Percent of
differentially
expressed Oct4
targets on Oct4
knockdown
Percent of
differentially
expressed Nanog
targets on Nanog
knockdown
ChIP-Chip only 33.9% (390/1151) 21.4% (192/898)
ChIP-PET only 29% (114/393) 14.8% (91/616)
ChIP-chip+ChIP-PET 70.3% (83/118) 33.5% (73/218)
% up (+) and down(-)
regulated genes
39.4% (+)
60.6% (-)
50.6% (+)
49.4% (-)
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Affymetrix probes) determined only by ChIP-chip, 33.9% were differentially
expressed upon Oct4 knockdown.  Similarly, 29% of the Oct4 targets detected
solely by ChIP-PET were differentially regulated.  Interestingly, for Oct4 targets
obtained by both ChIP-PET and ChIP-chip, 70.3% showed changes in gene
expression upon downregulation of Oct4.  In Nanog knockdown ES cells, 21.4%
of the targets determined solely by ChIP-chip, and 14.8% identified only by ChIP-
PET were differentially expressed compared to normal ES cells.  This percentage
increased for targets that were identified by both techniques, where 33.5% were
differentially regulated upon Nanog knockdown.  These analyses also showed
that among the differentially regulated targets of Nanog, the distribution between
up-and down-regulated genes upon Nanog knockdown was approximately equal.
However, in the case of Oct4 regulated targets, a larger percentage of genes
were downregulated (60.4%) upon Oct4 knockdown.  These results suggest that
both Nanog and Oct4 can potentially activate or repress their binding targets.
Therefore, these analyses have revealed a higher-value set Oct4 and Nanog-
regulated genes, by collectively examining the targets identified by ChIP-chip and
ChIP-PET.
The functional relevance of the ChIP-chip and ChIP-PET data, as examined by
GO analyses, had revealed that the Oct4 and Nanog bound regions were
significantly enriched for transcriptional and developmentally important regulators
of gene expression. Similar observations had been made earlier for these factors
in human ES cells as well (Boyer, Lee et al. 2005).  For instance, among genes
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that displayed changes in expression levels upon Oct4 RNAi-mediated
knockdown, certain genes including Sox2 and Rif1, which have important roles in
development, were bound by Oct4 in both ChIP-chip and ChIP-PET experiments.
However, other genes that play a part in cell-fate determination, such as Gdf3
and Notch4 (Zhu, Zhang et al. 2006; Andersson, Bertolino et al. 2007) were
bound by Oct4 only in the ChIP-chip experiments.  A separate set of differentially
expressed Oct4 targets, including Yap1 and Foxd3, which have been shown to
have developmentally important roles (Hanna, Foreman et al. 2002; Camargo,
Gokhale et al. 2007), were obtained only in the ChIP-PET data.  Similarly,
observations were made in the Nanog RNAi knockdown data, which showed
changes in expression of target genes identified both exclusively and collectively
by the two technologies.  Therefore, combining the binding data obtained by both
techniques, along with gene expression data has provided a more detailed
overview of the factors involved in the ES cell transcriptional circuitry.  Further
genetic studies of these regions will lend deeper insight into the mechanisms
governing ES cell biology.
DISCUSSION
ChIP-based technologies are being used extensively in identifying protein-DNA
interaction networks in a variety of cell types and a number of varying conditions.
In particular, ChIP-PET and ChIP-chip have been used to identify the mouse and
human ES cell transcriptional circuitries, which are largely regulated by the key
pluripotency factors, Oct4 and Nanog. Although each ChIP-based technology
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used in the identification of these networks has its distinct advantages, we find
substantial differences in the data derived through these different experimental
methods.  Recent technological comparisons have shown differences in the
results obtained by these methods, and illustrated the need to use these data in
a complementary manner (Euskirchen, Rozowsky et al. 2007). We have used
ChIP-chip to uncover genomic regions bound by Oct4 and Nanog in mouse ES
cells, and expanded on previously published ChIP-PET results, and find a large
number of binding sites identified exclusively by each technique. Therefore, using
these data in a complementary fashion provides a more detailed overview of the
Oct4 and Nanog transcriptional networks.
We analyzed our ChIP-chip results for Oct4 and Nanog in relation to existing
ChIP-PET data.  Since the criteria for identification of genomic targets is different
between platforms, the data sets obtained by the two methods was examined
against each other under an exhaustive range of significance values.  Recovery
curves were used to measure the recovery of targets obtained by keeping the
binding threshold for one technique constant and varying the threshold values for
the other method.  As expected, for both Oct4 and Nanog targets, the ChIP-PET
recovery decreased as the ChIP-chip p-value threshold was made more
stringent. A similar trend was observed for the ChIP-chip recovery when the
ChIP-PET read stringency was increased. Additionally, at the same thresholds,
this overlap decreased when the recovery distance permitted between a ChIP-
chip peak and ChIP-PET peak was narrowed. Therefore, these recovery curves
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revealed the necessity of recovery distance calibration in examining binding
experiments from multiple sources.  Interestingly, we also observed that the
amount of recovery between ChIP-chip and ChIP-PET data increased when the
whole chromosome arrays were used.  Therefore, the criteria used to determine
a binding event, as well as the extent of genome coverage had an effect on the
overlap between the data obtained by the two methods.  The recovery curves
illuminated the sensitivity of recovery to distance threshold, and provided a useful
means to examine the data sets relative to each other.
We combined the protein-DNA binding data with known Oct4 and Nanog RNAi
expression profiling data in order to analyze the targets that are differentially
regulated upon Oct4 or Nanog knockdown in ES cells. Oct4 and Nanog-bound
regions uncovered by both technologies, as well as the ones obtained exclusively
by each method contained a number of differentially regulated genes. Many of
these genes comprised of transcription factors and regulators of gene
expression, which are important in development.  For instance, the expanded
Oct4 and Nanog regulatory network contained genes such as, Hoxa1, Foxd3,
Msx2 and Hexb, which showed changes in expression upon Oct4 or Nanog
knockdown.  These genes have been shown to be important in cell fate-
specification, and are involved in developmentally important signaling pathways.
Such additional targets identified by each technique can be used to expand the
ES cell transcriptional regulatory framework, and thereby provide more detailed
groundwork to understand pluripotency mechanisms. Further genetic
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manipulations of each of these genes in ES cells would be necessary to
independently validate their contributions to pluripotency.
Although both ChIP-chip and ChIP-PET technologies have been useful in
studying protein-DNA interactions on a genome-wide scale, each method has its
set of limitations. In ChIP-chip, our observations are restricted to regions tiled on
the array platform, and the resolution is limited by the size of the probes, their
spatial distribution, as well as the average fragment length of sonicated DNA
hybridized to the arrays.  In ChIP-PET experiments, the bacterial cloning and
sequencing steps, as well as mapping issues introduce scope for error.  We feel
that a combination of more stringent mapping criteria and the inherent noise in
the sequencing procedure may be responsible for the number of sequence reads
which did not match perfectly to the genome. Moreover, as indicated by our
sequence-depth analysis, the number of sequences obtained from ChIP-PET
experiments can be a limiting factor, since more binding targets can be
recovered through greater depth in sequencing. Additionally, as in the case of
ChIP-chip experiments, the resolution of binding is limited by the average DNA
fragment size used in the ChIP experiment.  We observed some of these
limitations in this study since there were a significant number of Oct4 and Nanog
targets that had been identified by ChIP-PET, and did not have corresponding
probes tiled on the arrays used in the ChIP-chip experiments.  Apart from these
limitations, it is also important to consider that binding sites may be differentially
occupied at different times in the cell cycle since the chromatin state changes at
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different times (Meshorer and Misteli 2006).  However, since it is currently not
feasible to culture ES cells in a synchronized manner, such genome-wide
analyses should be done with this caveat in mind.  In addition to this, another
limitation to these studies is that the processing of ES cell samples can vary
between different laboratories and also between different batches of serum used
to culture these cells.  Finally, different binding results may be obtained due to
differences in ES cell strains. Therefore with the availability of binding information
from different cell strains (Kim, Chu et al. 2008), can begin to address such
issues.
Apart from ChIP-Chip and ChIP-PET, other ChIP based methodologies, such as
ChIP-SACO (Impey, McCorkle et al. 2004) and STAGE (Bhinge, Kim et al. 2007)
have been used to determine protein-DNA interactions on a genome-wide scale.
Most recently, ChIP-Seq (Johnson, Mortazavi et al. 2007), a sequencing based
technology has aimed to address many of the issues such as, genome coverage,
sequencing-depth and binding resolution, which are encountered by other
currently used techniques.  With this rapid change in technologies, it will be
important to investigate the results obtained from them techniques and
incorporate them into our current understanding of regulatory networks.
Importantly, the use of multiple techniques has been shown to produce variations
in the information obtained through individual platforms (Euskirchen, Rozowsky
et al. 2007).  Using the data obtained through these different methodologies in a
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complementary fashion provides a more thorough foundation for further
investigating these networks.
The results of this study provide a useful way to integrate protein-DNA interaction
data that are obtained by different techniques.  We have used this to expand our
current knowledge of the mouse ES cell regulatory network that is orchestrated
by the transcription factors, Oct4 and Nanog. Although both the ChIP-chip and
ChIP-PET technology platforms identified different sets of binding events, a
considerable number of these events represented genes that were regulated by
Oct4 and Nanog.  Since a number of these genes have known roles in important
developmental pathways and in cell-fate specification, it will be interesting to
explore their biological roles with respect to ES cell pluripotency.  Therefore, this
expanded network provides a stronger foundation to further examine biochemical
and genetic interactions that regulate stem cell properties.  Moreover, the
methods described to compare datasets from different platforms would be very
useful as data from newer technologies, such as Chip-Seq becomes available.
Since ES cells are a model system for studying developmental processes, and
are thought to hold great promise in regenerative medicine, it will be important to
gain a thorough understanding of the means by which a stem cell maintains its
identity, and how it can be directed to form different cell types.  Our work will
allow for a more detailed examination of the components of this expanded stem
cell circuitry and will lend better insight into the mechanisms of pluripotency.
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METHODS
ES Cell Culture
V6.5 murine ES cells (genotype 129SvJae x C57BL/6; male) were grown at 5%
CO2 at 37°C on gelatinized tissue-culture plates.  They were grown in DMEM
(Gibco, 11965-118) with 15% Fetal Bovine Serum (FBS) (Hyclone, Lot No.
ARC26080), Leukemia Inhibitory Factor, 1% penicillin/streptomycin (100X stock
from Gibco, 15140-122), 1% L-glutamine (200 mM from Gibco, 25030-081), 1%
non-essential amino acids (100X stock from Gibco, 11140-050) (Rideout,
Wakayama et al. 2000). Since the replication time of ES cells can vary with
different batches of serum, the doubling time of ES cells grown with this batch of
serum was calculated to be approximately 16 hours.  This doubling time was
comparable to that obtained with other lots of FBS (Hyclone, Lot numbers
ASJ30355 and ASB28896).  Moreover, as an additional control, KH2 ES cells
(Beard, Hochedlinger et al. 2006) were also cultured in these different batches of
FBS, and showed similar doubling times as v6.5 ES cells  The cells were grown
without irradiated mouse embryonic fibroblasts, prior to the ChIP analyses in
order to minimize contamination from feeders.
Antibodies
For ChIP experiments, we used anti-Nanog (Bethyl, BL-1162) and anti-Oct4
(SantaCruz, sc-8628X), which have been previously characterized for
immunoprecipitation.
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Chromatin Immunoprecipitation
The ChIP protocol was similar to previously published studies(Boyer, Lee et al.
2005; Boyer, Plath et al. 2006; Lee, Jenner et al. 2006; Lee, Johnstone et al.
2006).   Briefly, for each location analysis reaction, approximately 1.5x 108 ES
cells were grown at 70-80% confluency.  The cells were cross-linked by adding
fresh 11% formaldehyde solution to the ES media for 10 minutes at room
temperature.  The cells were washed twice with 1x PBS and scraped off the
plates, pelleted and stored at -80°C.  They were then lysed and sonicated to
solubilize chromatin and shear the cross-linked DNA.  Sonications were
performed with a Misonix Sonicator 3000 and sonicated at power 7 for 12 x 30
second pulses (60 second pause between pulses) at 4°C while the samples were
immersed in a water bath.  The whole cell extract was incubated overnight on a
rotating platform at 4°C with 100 µl of Dyna1 Protein G magnetic beads, blocked
with 0.05% BSA/PBS and preincubated for 6 hours to overnight with 10 µg of
antibody of choice.  The beads were washed 5 times with RIPA buffer and once
with TE containing 50 mM NaCl.  Bound protein-DNA complexes were eluted off
the beads in elution buffer by occasional vortexing and heating at 65°C overnight.
Whole cell extract (saved from the sonication step) was treated similarly for
cross-link reversal.   Following treatment with RNaseA and Proteinase K, the
immunoprecipitated and whole cell extract DNA was purified by
phenol:chloroform:isoamyl alcohol extraction.  The DNA was blunted-end ligated
to a universal linker and amplified using a two-stage expansion PCR protocol (3
reactions per sample were done for the second expansion and combined).  The
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amplified immunoprecipitated DNA and whole cell extract DNA were labeled with
Cy5 and Cy3 fluorophores respectively, using Invitrogen random primer labeling
kits.  1 ug of DNA was used in a labeling reaction and 3 labeling reactions were
done per sample and combined after purification.  The labeled DNA was purified
using Invitrogen BioPrime Array CGH module purification kit.  5 µg each of
immunoprecipitated and whole cell extract DNA was combined along with mouse
Cot-1 DNA and hybridized to each of the arrays in Agilent hybridization chambers
for 40 hours at 65°C using the Agilent hybridization protocol and reagents for
244K arrays.  Arrays were then washed and scanned as previously described.
Three biological replicates were done for each transcription factor in order to
determine statistical significance for binding targets.
Analysis of ChIP-Chip Data
Three biological replicates were examined for both Oct4 and Nanog using mouse
promoter arrays.  The same samples were also hybridized to mouse
chromosome arrays.  A probe was marked 'bound' in a particular replicate if its
Rosetta p-value was below a pre-determined cutoff (usually 0.001, although this
was systematically varied for the Recovery curves).  For each bound probe, a
region around the probe was marked 'bound' extending to the nearest unbound
probe (or 1kb, if the nearest probe was more than 1kb away).  A region was
marked as a ‘peak’ if it was bound in all three replicates.
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The list of micro-RNAs to be analyzed was taken from version 8.0 of mirBASE,
which were mapped against NCBI build 34 of the mouse genome (mm6).  We
retained for analysis only those micro-RNAs which had at least three probes from
the promoter array design mapped to within 4kb of the mirBASE annotation.  Of
the original 267 mirBASE annotations, 258 satisfied this requirement.
Mapping of ChIP-PET Sequences To The Mouse Genome
Two sets of previously published ChIP-PET experiments for Oct4 and Nanog
were examined. These reads were mapped to the Mouse mm6 genome
sequence in order to be consistent with the genome version used for the arrays
in the ChIP-Chip experiments.  The mapping was done using the BLAT
sequence alignment tool, with a step size of 5 and tile size of 11.
We received two FASTA files of sequences, each between 34-36 bp in length.
Only those sequence hits reported by BLAT that had at least 34 matched bases
(corresponding to 0, 1, or 2 mismatches), and a gap-length of at least 10bp, were
retained. Any sequences with more than one retained hit to the mm6 genome
were filtered out.  The locations of the unique hits for the sequences that
remained were stored in a database, and used for comparison with the ChIP-chip
peaks.
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Comparison of ChIP-Chip to Chip-PET Data
In order to examine if a bound region from ChIP-Chip was ‘matched’ to another
bound region from ChIP-PET, and vice versa, a simple genomic distance
threshold was determined.  If the two regions were on the same chromosome,
and if the edge of one region was within the recovery distance from the edge of
the other, then they were considered ‘matched’.  The typical recovery distance
used was 1kb, although this was varied systematically for the recovery curves. A
recovery distance of '0' represents only strictly overlapping regions that were
matched to each other.
Recovery Curves
Recovery curves were produced for promoter and chromosome array data for
Oct4 and Nanog.  One curve was for the ChIP-Chip (p-value) cutoff, and the
other for the ChIP-PET (overlapping region) cutoff.  In the ChIP-PET Recovery
curves, fixed cutoffs of 4 overlapping reads for Oct4 and 3 overlapping reads for
Nanog were used to determine a 'background set' of ChIP-PET bound regions,
as described above. At that ChIP-PET cut-off, the number of ChIP-Chip bound
regions was calculated for a range of p-value cut-offs.  The percentage of
background ChIP-PET bound regions that were matched by at least one ChIP-
Chip bound region, at each p-value threshold was graphed.  This was repeated
for several different matching distances.
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For calculating the ChIP-Chip Recovery curve, this process was repeated by
holding the ChIP-Chip binding threshold constant.  A background set of bound
regions using ChIP-Chip was calculated using a p-value threshold of 0.001.  The
threshold of overlapping reads used to call bound regions in ChIP-PET was
varied from 1 to an upper limit where no matched regions were called.  At each
threshold, the fraction of the background ChIP-Chip bound regions matched by
one of the ChIP-Pet regions was calculated.  This process was also repeated for
several different matching distances.
Sequence Depth Analysis
In order to carry out the sequence-depth analysis using data from chromosome
19, the total number of ChIP-PET reads for Oct4 and Nanog were calculated.
For Oct4, 8675 reads, and for Nanog, 5233 reads were mapped to Chromosome
19.  The number of ChIP-chip bound regions recovered for both proteins, was
determined for differently sized subsets of these ChIP-PET reads.  We started
with a random subset that sampled 10% of the reads, and determined the ChIP-
ChIP recovery for that sample.  This analysis was done for increasingly large
subsets of ChIP-PET reads in increments of 10%, until all ChIP-PET reads on
chromosome 19 were sampled.  For each subset size, the same number of reads
was randomly sampled 10 times to calculate the average ChIP-chip recovery and
standard deviation in each case.
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Expression Analysis of Oct4 and Nanog Targets
We wanted to determine the relevance to pluripotency for Oct4 and Nanog
binding targets obtained by ChIP-Chip or ChIP-PET.  Previously published Oct
and Nanog RNAi gene expression profiles in ES cells were used for this
analysis(Loh, Wu et al. 2006).  These experiments produced sets of Affymetrix
probes, which were differentially-regulated in one or more of the replicates.
Those probes were matched to sets of gene names using an Affymetrix-provided
probe annotation file.  A gene was determined as differentially-regulated in either
the Oct4 or the Nanog knockdown experiments if it was associated with any
differentially-regulated probe in the replicates of that factor's experiments.  A
gene annotation was called ‘bound by ChIP-chip’ if there was a ChIP-chip peak
within +/-4kb of the gene annotation's start site.  Equivalently, a gene annotation
was also bound by ChIP-PET if a ChIP-PET peak fell within the same distance of
the annotated start site.  This allowed us to divide the set of differentially
regulated gene annotations into four categories: bound in both experimental
types, bound in neither, and bound in one (but not the other).
Gene Ontology (GO) Analysis
A set of bound RefSeq gene identifiers was compiled for the Oct4 and Nanog
bound genes according to a standard cutoffs (p-value< 0.001 for ChIP-chip, and
a maximum distance of 4kb from the gene start site for any annotated gene). The
sets of RefSeq identifiers were converted into sets of Known Gene gene
symbols, using the kgXref table of the UCSC Genome database. A set of GO
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categories was downloaded from the Gene Ontology Project
(http://www.geneontology.org/GO.downloads.ontology.shtml), and an updated
set of mouse annotations was downloaded from EBI
(http://www.ebi.ac.uk/GOA/). Since the GO categories are structured as a
directed graph, we propagated the annotations backwards through the graph; a
gene symbol was marked as annotated to a GO category if the annotation was
contained in the EBI dataset, or if the GO category was the ancestor of a GO
category to which the gene symbol had already been assigned. A background
set of gene symbols was assembled, from the corresponding Known Gene
symbols for any RefSeq gene identifier that was tiled on the ChIP-chip array
design. Given foreground sets of genes defined by the ChIP binding
experiments, a background set of arrayed gene symbols, and a set of EBI-
derived GO category annotations for each symbol, we calculated a list of GO
categories ranked by their enrichment in each of the four foreground gene sets.
Enrichment was calculated using the p-value of the hypergeometric probability
for the overlap of each test set with each GO category.
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SUPPLEMENTARY INFORMATION
Supplementary Note
We have summarized the ChIP-chip promoter (supplementary file A) and
chromosome array data (supplementary file B) and ChIP-PET raw data for Oct4
and Nanog. The ChIP-chip data for each region contains the location and value
of each probe in that region (the first number is the locations, and the second
number, marked with a ‘+’, is the offset of that probe within that region).  Each
probe is followed with its binding ratio in each of the three replicates.  A bound
probe is marked with a ‘*’.  A second list represents a set of coordinates for each
distinct ChIP-PET read that falls within that window.  The numbers marked with a
‘+' represent the offset within that region.
Oligo Array Design
Two kinds of array platforms were employed in this study.  One was a 2-slide
mouse promoter array that is based on the 10-slide mouse promoter array set
described in previous studies (Boyer, Lee et al. 2005; Boyer, Plath et al. 2006).
The arrays were manufactured at Agilent Technologies (www.agilent.com).  The
arrays include 19.993 features that include the promoters of all annotated genes
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in the NCBI Refseq database and miRNAs in miRBase.  They also include
promoters of alternate transcription start sites (TSSs).  The oligos are 60-mers
and span from 4kb upstream to 4kb downstream of the TSS at a density of one
probe every 250 bp.  Additionally the entire mouse HoxA cluster is also tiled on
these arrays.
The second type of array was a whole chromosome array for the mouse
chromosome 19.  It also tiles the non-repeat portion of the ENCODE Design.
Since ENCODE is a human project, analogous regions in mouse were mapped
for this array.  The oligo length and probe density is similar to the promoter
arrays.
Gene Specific PCR For Oct4 and Nanog Bound Regions
Gene Specific PCR was performed for three different sets of targets for both
Oct4 and Nanog: targets identified solely by ChIP-Chip, ones identified only by
ChIP-PET and another set uncovered using both methods. PCR was performed
on the Ligation-mediated PCR products for two independent biological replicates
for each protein.  10 ng of immuno-enriched DNA and 10, 30 and 90 ng of whole-
cell extract DNA were used per reaction.  The PCR was run for 23 cycles, and
products were quantified on an agarose gel stained with SYBR Gold (Invitrogen).
Primers for each target amplified a 200-300 bp region around the genomic
locations of the probes showing enrichment.  The primer sequences and PCR
product coordinates can be found in Table S9.  Enrichment was calculated as a
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ratio of intensity of PCR product from 10 ng of IP DNA to the product intensity
from 90ng or 30 ng of WCE DNA.  For a product to be considered enriched, the
IP DNA product intensity had to be atleast that of 90 ng of WCE DNA or 1.5
times that of 30 ng of WCE DNA.  Enrichment ratios were normalized against the
ratio for un-enriched β-Actin DNA.  Among Nanog bound targets found
exclusively by ChIP-chip, 26 of 33 regions were confirmed by gene-specific PCR
experiments.  Similarly, 28 out of 31 Oct4-bound regions, identified solely by
ChIP-chip were unenriched (Table S9).
Gene Expression Analysis Note
A caveat in this analysis was that the gene-expression comparison to binding
data was limited to –4 to +4 kb surrounding the transcriptional start site for both
ChIP-Chip and ChIP-PET data.  Such a restriction was necessary for this
comparison since probes on the promoter arrays used in ChIP-chip experiments
are limited to these regions.  Therefore, a binding event outside of this 8kb region
in the ChIP-PET data would not be captured in our analysis.  An example of this
is demonstrated in Supplementary Figure S3, where the Rest gene, which is
differentially expressed on Oct4 knockdown, is bound by Oct4 in both
experiments.  However, in our analysis of the expression data, it is observed as
an Oct4 target only by ChIP-chip and not by ChIP-PET since the binding event in
the latter case is outside the promoter array tiled region.  Visualization of the two
experimental types on the ‘GSE Visualizer’ reveals the utility of careful calibration
of the thresholds at which binding events are called significant.
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Figure S1.  Oct4 ChIP-Chip Enrichment plots.  IP vs. WCE enrichment in three
biological replicate samples is shown for (a) the 2-slide set promoter arrays and
(b) chromosome 19 arrays.
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Figure S2. Nanog ChIP-Chip Enrichment plots.  IP vs. WCE enrichment in
three biological replicate samples is shown for (a) the 2-slide set promoter arrays
and (b) chromosome 19 arrays.
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Figure S3.  Sequence Depth Analysis for OCT4 and NANOG Targets on
Chromosome 19.  Plots indicate the number of ChIP-chip targets recovered (y-
axis) when different percentages of ChIP-PET sequences are randomly sampled.
Error bars represent the standard deviation.
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Figure S4. Inconsistency in combining expression-profiling data with
binding information from ChIP-Chip and ChIP-PET.  The binding of Nanog at
the REST gene promoter is identified by both ChIP-Chip and ChIP-PET.
However, the binding event detected in the ChIP-PET experiment is not within
the region used for combining the expression profiling information (+/- 4kb
around the transcription start site).  Consequently, the changed expression of
REST after Nanog knockdown is associated with Nanog binding detected by
ChIP-Chip only and not ChIP-PET.
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Additional Data Files on CD
Table S1.  Protein Coding Gene List (Excel format)
Table S2.  miRNA Targets
Table S3.  Gene Ontology Analysis
Table S4.  Chromosome 19 Bound Regions for Oct4 and Nanog
Table S5.  Oct4 Recovery Curve Tables
Table S6.  Nanog Recovery Curve Tables
Table S7.  Oct4 RNAi Differentially Regulated Targets
Table S8.  Nanog RNAi Differentially Regulated Targets
Table S9.  Gene-Specific PCR Regions for Oct4 and Nanog Genomic Targets
Table S10.  Sequence Depth Analysis of Oct4 and Nanog ChIP-PET data
Supplementary File A.  Promoter Array and ChIP-PET Data for Oct4 and Nanog
Supplementary File B.  Chromosome Array and ChIP-PET Data for Oct4 and
Nanog
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ABSTRACT
The reprogramming of somatic cells into a pluripotent state through virus-
mediated transduction of four transcription factors has been a major feat for the
scientific and medical communities.  However, before these induced pluripotent
(iPS) cells are employed in medical treatments, issues such as drug selection,
use of viruses and introduction of potentially oncogenic transcription factors need
to be resolved.  Therefore, in order to design screening procedures for finding
safer alternatives, iPS cells obtained from different screens must be better
characterized.  One issue with earlier experiments that used activation of Fbx15
as a selection criterion for reprogramming was that the Fbx15-iPS cells were not
truly pluripotent and did not give rise to chimeras.  In contrast, selection for Oct4
or Nanog activation, albeit with later drug initiation, led to iPS cells that could
generate germline chimeras.  Therefore, it was unclear whether the partially-
reprogrammed Fbx15-iPS cells were obtained due to early drug selection, or
because selection for Fbx15 activation led them down this path.  We examined
Fbx15-iPS cells, obtained from early and late drug selection, by examining the
methylation status of the Oct4 locus.  Since this locus is methylated in the former
case and completely unmethylated in the latter, our results support the notion
that early drug selection leads to the partially-reprogrammed intermediates.
Therefore, Fbx15 activation may be employed as a useful marker in
reprogramming screens in the future.
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INTRODUCTION
Embryonic Stem (ES) cells possess the valuable property of pluripotency, and
therefore hold great potential in medical applications.  However, since the
derivation of these cells involves the destruction of an embryo, research involving
these cells had been plagued with ethical controversies.  Recently, after many
attempts at circumventing the use of embryos to obtain ES cells, scientists were
successful in reprogramming the genomic state of differentiated skin fibroblasts
back into an ES cell-like state (Takahashi and Yamanaka 2006; Maherali,
Sridharan et al. 2007; Okita, Ichisaka et al. 2007; Wernig, Meissner et al. 2007).
These reprogrammed cells are known as induced pluripotent stem (iPS) cells.
Reprogrammed iPS cells were generated by introducing four transcription factors
into fibroblasts through virus-mediated transduction.  These pluripotency factors
were Oct4, Sox2, c-Myc and Klf4.  In the initial reprogramming experiments, the
activation of the fbx15 gene locus was used as a marker to select for
reprogrammed ES cells (Takahashi and Yamanaka 2006).  The iPS cells
generated in this experiment were termed Fbx15-iPS cells, and were thought to
be pluripotent since they could form teratomas when injected into mice.
However, these cells were unable to generate any chimeras, indicating that they
were not truly pluripotent, and may represent an intermediate stage in the
reprogramming process.
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Activation of the fbx15 locus was used as a selection criterion in initial
reprogramming experiments since this gene is expressed predominantly in ES
cells and is a direct target of Oct4 (Tokuzawa, Kaiho et al. 2003).  Fbx15 belongs
to a family of F-box containing proteins, which are components of E3 Ubiquitin
ligases (Winston, Koepp et al. 1999).  The promoter of this gene contains an
enhancer element that has an octamer-like motif and a sox-binding motif.  Oct4
and Sox2 can bind to these motifs, respectively, and activate the enhancer.  In
fact, Oct4 is required for the maintenance of fbx15 gene expression.  However,
fbx15 knockout mice and ES cells are normal, indicating that the gene is
dispensable for pluripotency, development and fertility (Tokuzawa, Kaiho et al.
2003).
Since Fbx15-iPS cells failed to produce chimeras, later reprogramming
experiments used activation of Oct4 or Nanog loci as selection criteria for
reprogramming.  As described in earlier sections, these genes are not only
expressed exclusively in pluripotent cells, but are also key regulators of
pluripotency (Niwa, Miyazaki et al. 2000; Chambers, Colby et al. 2003; Mitsui,
Tokuzawa et al. 2003). In contrast to the Fbx15-iPS cells, when Oct4 or Nanog
were used as markers to select for reprogramming, completely reprogrammed
iPS cells were generated, which could give rise to germline chimeras (Okita,
Ichisaka et al. 2007; Wernig, Meissner et al. 2007).  Moreover, the Oct4 and
Nanog loci were completely unmethylated in these cells and ES cells, but were
still partially methylated in Fbx15-iPS cells.  The expression levels of key
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pluripotency markers in Nanog-iPS cells were higher than in Fbx15-iPS cells, and
more similar to those in ES cells.  These studies suggested that activation of
Oct4 or Nanog was a more stringent criterion that Fbx15 selection, in order to get
fully reprogrammed cells.
A key difference between the initial reprogramming experiments with Fbx15
activation (Takahashi, Tanabe et al. 2007), and later ones with Oct4 or Nanog
activation (Okita, Ichisaka et al. 2007; Wernig, Meissner et al. 2007) was that in
the former case, fibroblasts infected with viruses carrying the Oct4, Sox2, Klf4
and c-Myc transgenes were selected for Fbx15 expression at an earlier time
point than in the latter case, where drug selection for Oct4 or Nanog expression
was started later.  Further studies on Oct4- and Nanog-iPS cells have shown that
pluripotency markers, such as Alkaline Phosphatase (AP), Stage-specific
embryonic antigen 1 (SSEA1), Oct4 and Nanog are sequentially reactivated
during the reprogramming process (Brambrink, Foreman et al. 2008; Stadtfeld,
Maherali et al. 2008).  Moreover, there is a discrepancy in the timing between the
appearance of drug resistance cells and fully reprogrammed ones, suggesting
that early colonies may have low levels of pluripotency gene expression, which is
sufficient for antibiotic resistance but not for epigenetic reprogramming.
Additionally, fewer reprogrammed cells are obtained when drug selection is
initiated early, but many more iPS colonies are observed with later or no drug
selection (Meissner, Wernig et al. 2007; Wernig, Meissner et al. 2007).  All these
observations raise the possibility that the partially reprogrammed Fbx15-iPS cells
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were obtained due to early drug selection and incomplete epigenetic
reprogramming, and not due to the fact that Fbx15 is not relevant to pluripotency.
Therefore, we tested this hypothesis by selecting for fbx15 at early and late time
points, and examining the epigenetic state of the Oct4 locus.  Indeed, we
observed that in Fbx15-iPS cells that are obtained from late drug selection, the
Oct4 locus is completely unmethylated, similar to what has been reported for ES
cells and Nanog iPS cells (Okita, Ichisaka et al. 2007).  However, in Fbx15-iPS
cells that had early drug selection, the Oct4 locus was largely methylated,
indicating that epigenetic reprogramming had not completely occurred in these
cells.  The experiments described here suggest that similar to Oct4 or Nanog,
activation of the Fbx15 locus can also be used as a criterion for reprogramming,
and the partially reprogrammed cells are observed due to early drug selection
that leads to incomplete epigenetic reprogramming.
RESULTS
Generation of Fbx15-βgeo mice and fibroblasts
In order to develop a selection scheme for activation of the Fbx15 locus, a β-geo
cassette (a fusion of the β-galactosidase and neomycin resistance genes) was
used to replace exons 3 to 7 of the fbx15 gene (Figure 1a).  This vector was
targeted to the Fbx15 locus by homologous recombination and positive clones
were screened by Southern blot analysis (Figure 1b). Four out of forty six
resistant colonies were correctly targeted and one of these clones was injected
into C57/BL6 blastocysts to obtain chimeric mice containing the targeted allele.
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Figure 1.  Generation of Fbx15-βgeo Mice.  (a) Targeting strategy to replace
exons 3-7 of the Fbx15 gene with a β-geo cassette.  (b) Southern blot indicating
ES cells clones correctly targeted with the Fbx15-β-geo construct.  Untargeted
ES cells were used as controls.  A 7.4 kb band represents the wild type Fbx15
allele, and a 6.8 kb band is of the targeted allele.  (c) Mice carrying the Fbx15-β-
geo allele in their germline were genotyped by a PCR strategy that amplified a
500 bp region of the β-galactosidase gene. Mice heterozygous for the targeted
allele are represented by +/-. Fbx15-β-geo ES cells that were injected into
blastocysts to make chimeras were used as positive controls.  Untargeted ES
cells served as negative controls.
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These chimeras were mated with B6D2F1 mice and offspring containing the
Fbx15-βgeo allele were obtained.  These mice were genotyped using a PCR
strategy that screened for the presence of the β-galactosidase gene (Figure 1c).
Since the Fbx15-βgeo construct had been targeted to ES cells containing a
puromycin resistance marker, MEFs were generated from chimeric embryos
made by injecting clones of the correctly targeted ES cell line into C57/BL6
blastocysts.  MEFs containing the Fbx15-βgeo allele were selected with
puromycin, and used for the experiments described below.
Reprogramming of Fbx15-βgeo fibroblasts with early and late drug
selection
Fbx15-iPS cells were obtained by infecting Fbx15-βgeo fibroblasts with
lentiviruses containing transgenes for the transcription factors, Oct4, Sox2, Klf4
and C-myc.  As a control, Nanog-neo fibroblasts were also infected with these
factors to obtain Nanog-iPS cells.  Colonies were observed in both cases after
initiating neomycin drug selection at days 3, 6, 9 and 15 post-infection.
Additional controls without any drug selection were also done for both Fbx15-
βgeo and Nanog-neo fibroblasts.  Colonies were counted 21 days post-infection,
based on morphological resemblance to ES cells (Figure 2a).  As shown in
Figure 2b, early drug selection in both cases resulted in very few neomycin-
resistant colonies.  In accordance with previous observations, the number of
resistant colonies obtained increased when drug selection was started at later
time points.  It was interesting to note that at later time points of drug initiation,
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Figure 2.  Analysis of Fbx15-iPS cells after Early and Late Drug Selection.
(a) Morphology of Fbx15- and Nanog-iPS cells obtained after early (day 3) and
late (day 9) drug selection.  (b) Colony counts of Fbx15-iPS cells and Nanog-iPS
cells obtained after drug initiation at different time points.  (c) Immunostaining of
early (day 3) and late (day 15) drug selected Fbx-15 iPS colonies for pluripotency
markers, Alkaline phosphatase (AP), SSEA1, Oct4 and Nanog.  (d) Bisulfite
sequencing of Oct4 and H19 DMR (control) loci in early (day3) and late (day 15)
drug selected Fbx15-iPS cells.
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substantially more iPS cells were obtained by selection for Fbx15 than for Nanog.
This observation has also been noted before (Okita, Ichisaka et al. 2007),
although the reason for this difference in numbers remains unclear.
We performed immunostaining for the presence of the pluripotency markers, AP,
SSEA1, Oct4 and Nanog in Fbx15-iPS cells obtained from drug selection initiated
at different time points.  Figure 2c shows that whereas AP and SSEA1 staining
was seen in most if not all iPS cells, staining for Oct4 and Nanog was seen at
greater intensity only in iPS cells obtained with late drug selection (days 9 and
15) or no selection. Moreover, bisulfite sequencing of the endogenous Oct4 locus
revealed that in Fbx15-iPS cells obtained from early drug selection, the locus
was largely methylated.  On the other hand, in Fbx15-iPS cells attained from late
drug selection, the Oct4 locus was completely unmethylated, as reported for
Nanog-iPS cells and ES cells (Okita, Ichisaka et al. 2007).  The control H19 DMR
region was methylated in both cases (Figure 2d).  These observations seem to
suggest that early drug selection prevents complete epigenetic reprogramming
and reactivation of pluripotency markers, thereby leading to partially
reprogrammed intermediates.  The use of Fbx15 activation as a selection
criterion has little or no bearing on the process of complete reprogramming.
DISCUSSION
The generation of iPS cells by in vitro reprogramming of somatic cells has been a
remarkable achievement for the scientific and medical communities.  These cells
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have been shown to hold the same potential that ES cells have in the treatment
of different diseases, and are not plagued by the moral dilemmas surrounding ES
cells. In proof-of-principle experiments, iPS cells have been used to treat a
mouse model of sickle-cell anemia (Hanna, Wernig et al. 2007), as well as
alleviate symptoms of Parkinson’s disease in a rat model of the disorder (Wernig,
Zhao et al. 2008).  This process of reprogramming by the introduction of fhe
transcription factors, Oct4, Sox2, Klf4 and c-Myc has also been accomplished in
human cells (Takahashi, Tanabe et al. 2007; Yu, Vodyanik et al. 2007; Park,
Zhao et al. 2008).
Despite this significant progress in reprogramming, not much is known about the
mechanism by which this process occurs.  Before iPS cells are used in medical
applications, it will be important to gain more insight into the process by which
they are obtained.  As mentioned earlier, recent studies have begun to show that
different markers of pluripotency, such as AP, SSEA1, Oct4 and Nanog are
sequentially activated during the course of reprogramming (Brambrink, Foreman
et al. 2008; Stadtfeld, Maherali et al. 2008).  The presence of all these markers is
indicative of complete reprogramming, since cells obtained at earlier time points
are not pluripotent.  Moreover, expression of the transgenes encoding the four
reprogramming genes is required for at least 12-16 days in order to get stably
reprogrammed cells.  In addition to this, it is also known that early drug selection
for the activation of ES cell markers leads to fewer reprogrammed cells, and
starting such selection at later time points greatly increases the number of
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reprogrammed cells obtained (Meissner, Wernig et al. 2007; Wernig, Meissner et
al. 2007).
Although these studies had shed some light on the mechanism of
reprogramming, it was not clear whether the choice of selection marker used for
obtaining iPS cells had an effect on the reprogramming process.  This question
arose from the observation that iPS cells selected for the activation of Oct4 or
Nanog were truly pluripotent, but those selected for Fbx15 were only partially
reprogrammed, and represented an “intermediate” stage in reprogramming.
Since iPS cells in the former case had been obtained after initiating drug
selection at a later time point than in the latter case, another possibility was that
these intermediates were seen due to early drug initiation.
In order to test both these possibilities, we performed reprogramming
experiments with Fbx15-βgeo fibroblasts while initiating drug selection at different
time points, and analyzed the iPS cells from each experiment by counting the
number of drug-resistant colonies obtained at each time point, staining for the
presence of pluripotency markers and examining the methylation status of the
Oct4 locus.  In accordance with previous observations, our results indicated that
later initiation of drug selection led to more resistant colonies.  Although all
colonies showed expression of the pluripotency markers AP and SSEA1, only
those at later time points stained positive for Oct4 and Nanog.  It was not clear
why all cells did not express Oct4 since they had been infected with a virus that
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constitutively expressed the gene.  It is possible that at the time of
immunostaining the viral transgene was not expressed at a level that was high
enough to be detected by this method.  Regardless, the bisulfite sequencing
results showed that the Oct4 locus in colonies obtained with early drug selection
was largely methylated, whereas it was completely unmethylated in cells from
late drug selection.  These results suggested that early initiation of drug selection
led to partially reprogrammed or “intermediate” cells since late selection for
Fbx15 activation led to fully reprogrammed cells, as indicated by complete
epigenetic reprogramming of the Oct4 locus.  Such epigenetic reprogramming is
possible at later stages of the process since de novo methyltransferases Dnmt3a
and Dnmt3b are reactivated later.
An interesting observation in this study came from a comparison of colony counts
between Fbx15- and Nanog-iPS cells.  Even though the same number of
fibroblasts had been infected with the reprogramming factors in both cases, the
number of colonies obtained from Fbx15 selection was greater than from Nanog
selection.  This observation has also been made earlier by Yamanaka and
colleagues, where the induction efficiency of Nanog-iPS cells was one-tenth that
of Fbx15-iPS cells (Okita, Ichisaka et al. 2007).  Although the reason for this
difference in induction efficiency is not clear, it is possible that this discrepancy
arose since the fibroblasts were of different passage numbers.  In our
experiments, the Fbx15-βgeo fibroblasts were of a much lower passage number
(Passage 2) than the Nanog-neo fibroblasts, which may have provided them with
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some growth advantage.  If this is the case, then an experiment comparing
induction efficiencies of Fbx15-βgeo and Nanog-neo fibroblasts of the same
passage number will address this issue.  The alternative possibility is that
selection for Fbx15 activation leads to greater enrichment for drug resistant cells
than selection for Nanog does.  The proportion of completely reprogrammed cells
in both these cases can be compared by including an Oct4-GFP marker in the
fibroblasts, and screening for GFP-positive clones.  If the proportion of GFP-
positive cells is higher for Fbx15-iPS cells, then Fbx15 may be a more useful
marker to enrich for fully reprogrammed cells.  However, if this number is lower
than that for Nanog-iPS cells, then Fbx15 selection may lead to enrichment for
intermediates in the reprogramming process.
The results of this study emphasize the need for appropriate timing of drug
selection for complete reprogramming, and indicate that Fbx15 could be added to
the repertoire of selection markers that can be used in reprogramming assays.  A
number of technical issues still need to be addressed before iPS cells or their
derivatives can be used in a patient.  These include elimination of virus-mediated
transduction of transgenes, since the integration of viruses in the host genome
could be harmful.  Moreover, even though iPS cells can now be derived without
the oncogene c-Myc (Nakagawa, Koyanagi et al. 2008; Wernig, Meissner et al.
2008), it is still unclear whether the introduction of the other three factors will lead
to tumors at later stages.  In order to address many of these issues it will be
necessary to screen for safer substitute factors or chemicals that can be used to
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obtain iPS cells.  In such screens, it may be advantageous to use ES cell
markers, such as Fbx15 to select for reprogramming, while the expression of
genes like Oct4 and Nanog, which are relevant to pluripotency, can be
maintained at endogenous levels.  The identification of other such markers may
be useful in the future as different screening methods are devised to reprogram
differentiated cells back to an embryonic state.
METHODS
Generation of Fbx15-βgeo ES cells and Mice
The strategy for generating the Fbx15-βgeo targeting construct was similar to the
one described earlier (Tokuzawa, Kaiho et al. 2003), which replaced exons 3 to 7
of the Fbx15 gene with an IRES (internal ribosome entry site)-βgeo (fusion of
genes encoding for β-galactosidase and neomycin-resistance) cassette
(Mountford, Zevnik et al. 1994).  The construct was linearlized with SpeI and
introduced into ES cells by electroporation. These ES cells had been derived
from matings between mice that had a doxycycline-inducible Oct4 construct in
the Collagen 1a1 locus (Hochedlinger, Yamada et al. 2005), and those that had a
doxycycline-inducible Nanog construct in the same locus.  Therefore, the ES
cells used for targeting had inducible Oct4 and Nanog constructs in the collagen
locus and a copy of the M2rtTA reverse transactivator in the Rosa26 locus
(Beard, Hochedlinger et al. 2006).
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Targeted ES cells were selected with neomycin (350 µg/ml), and antibiotic-
resistant colonies were screened for homologous recombination by Southern blot
analysis. DNA was isolated from 46 neomycin-resistant colonies, digested with
HindIII and run on a 0.8% agarose gel.  The DNA was nicked by soaking the gel
in 0.25M HCl for 15 minutes.  The gel was then soaked for another 15 minutes in
0.4M NaOH and the DNA was transferred to a nitrocellulose membrane in the
same solution.  After the transfer was complete, the membrane was washed in
0.2M Tris, pH 7.0 and 2X SSC for 30 seconds each, and air-dried.  The
membrane was prehybridized in Church buffer for 15 minutes at 65°C.  A
Strategene kit for labeling DNA was used to label 30 ng of probe with P-32, and
purified probe was added to the membrane and Church buffer.  After an
overnight hybridization with the probe, the membrane was washed with 2X SSC,
0.2% SDS for 15 minutes at room temperature, then twice for 30 minutes each
with 0.2% SSC, 0.2% SDS at 65°C.  The membrane was exposed to an
autoradiography film overnight at -80°C. The 500 bp external 3’ probe from intron
8 (+31400 to +31999 bp) and produced A 7.4 kb band from the wild-type locus
and a 6.8 kb band from the targeted one.  PCR primers for amplifying this probe
were: Forward (ATGTCTTGCTCTTTGGA GGGAGGCAG) and Reverse
(TCCTCTGTACCTCCTCATGAGCATTC).
An ES cell clone that was correctly targeted with the Fbx15-βgeo construct was
injected into diploid C57/BL6 blastocysts according to previously described
procedures (Meissner, Wernig et al. 2007).  These blastocysts were implanted in
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pseudopregnant B6D2F1 females in order to obtain chimeric pups.  Two
embryos were extracted early at d13.5 in order to generate mouse embryonic
fibroblasts (MEFs).  MEFs from each embryo were selected with Puromycin
(2µg/ml) after 24 hrs for 1 week.  This selection eliminated all wild-type MEFs
and only those carrying the Fbx15-βgeo remained on the dishes.  These cells
were expanded, frozen down, and used in the reprogramming experiments
described here.  The chimeras obtained were mated with B6D2F1 females to
obtain germline transmission of the Fbx15-βgeo construct.  Male and female
mice carrying the targeted allele in their germline were obtained and screened by
a PCR screening strategy.  PCR primers were used to amplify approximately 500
bp of the region encoding for β-galactosidase in the Fbx15-βgeo construct:
Forward (CGGTGATGGTGCTGCGTTGG) and Reverse (GAATCAGCAACGGC
TTGCCG).  The reaction was set up as described below:
LacZ PCR Reaction for Genotyping Fbx15-βgeo Mice:
Template DNA: 1 µl
10X Buffer (USB Fidelitaq): 2 µl
50 mM MgCl2: 0.8 µl
10 mM dNTP: 0.4 µl
20 µM primer mix: 0.2 µl
Taq (USB Fidelitaq): 0.2 µl
dH2O: 15.4 µl
Total Volume = 20 µl
PCR Cycle
1. 95°C: 1 min
2. 95°C: 45 s
3. 55°C: 45 s
4. 72°C: 1 min
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5. Repeat steps 2-4 35X more
6. 72°C: 10 min
Viral infections and Drug Selection Experiments
Lentiviral constructs that constitutively expressed the Oct4, Sox2, Klf4 and c-Myc
transgenes, and virus preparation methods have been described previously
(Brambrink, Foreman et al. 2008).  Viruses carrying the four transgenes were
used to infect 2.5x104 Fbx15-βgeo and Nanog-neo MEFs/10 cm2 plate coated
with 0.2% gelatin.  Neomycin selection was started at days 3, 6, 9 and 15 for
both types of MEFs, and the media was changed every other day.  Additional
plates with no drug selection were also included in the experiment.  The selection
was carried out for 21 days, after which drug resistant colonies that
morphologically resembled ES cells were scored, picked and passaged.
Immunostaining protocol
For immunostaining, iPS cells were grown in 6-well dishes on feeders.  After
removing the ES cell media, they were washed once with Hepes buffer.  Using a
cotton tip applicator, each well was marked along its edge and divided into four
quadrants.  These edges were then sealed with a pap-pen.   The cells were fixed
in 4% paraformaldehyde for 30 minutes at room temperature, and washed once
with 1X PBS.  For the quadrants in which AP staining was done, an AP staining
kit for Vector was used.  Briefly, in 5 ml of AP buffer (100 mM Tris, pH 8.3) 2
drops of reagents 1, 2 and 3 were added.  This solution was added to the cells
that were stained for AP, and was removed after 10 minutes when positive
130
controls stained red for the presence of AP.  In the other quadrants, cells were
stained for the presence of SSEA, Oct4 and Nanog.  These wells were blocked
with 5% CCS (Cosmic Calf Serum).  For cells that were to be stained for Oct4
and Nanog, 0.1% TritonX-100 was also added to the blocking solution to
permeablize the cells.  After removing the block, primary antibodies against Oct4
(Santa Cruz, sc-9081 (H-134)), Nanog (Bethyl, BL1662) and SSEA1
(Developmental Studies Hybridoma Bank) were added at a dilution of 1:100 in
0.1% FBS, 0.1% TritonX-100 (no TritonX-100 was used for SSEA1 staining), and
incubated overnight at 4°C.  The cells were washed 3x with 1X PBS and
incubated with secondary antibodies (in the same solutions used for diluting the
primary antibodies) for 1.5 hours at room temperature.  The cells were then
counterstained with DAPI for 5 minutes and washed 3 times with 1X PBS.
Immmunofluorescence was detected using an Olympus Fluorescence
microscope and pictures were taken with a Zeiss Axiocam camera.
Bisulfite sequencing protocol
For bisulfite sequencing, iPS cells were grown in 6-well plates.  For DNA
preparation, the cells were washed once with Hepes buffer and incubated in 500
µl of lysis buffer containing 200 µg/ml of Proteinase K for 2 hours at 37°C.  The
DNA was then extracted with an equal volume of Phenol/choloroform using
phaselock tubes (Eppendorf), followed by an isopropanol and ethanol
precipitation.  DNA was suspended in 150 µl of TE buffer and incubated
overnight at 55°C.  2µg of DNA was used for bisulfite treatment according to the
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protocol described in the Epitect Bisulfite Kit (Qiagen).  The treated DNA was
purified and eluted in 20 µl of elution buffer, and used in the following nested
PCR reactions to examine the methylation status of the Oct4 locus and H19
DMR region:
Oct4 PCR Reaction 1
Template DNA: 1.5 µl
10X Buffer: 2.5 µl
50 mM MgCl2: 1 µl
100 µM Primer F1: 0.25 µl
100 µM Primer R: 0.25 µl
10mM dNTPs: 0.5 µl
Taq: 1 µl
dH2O: 18 µl
(Total Volume = 25 µl)
Oct4 PCR Reaction 2
Template DNA (from reaction 1): 1 µl
10X Buffer: 2.5 µl
50 mM MgCl2: 1 µl
100 µM Primer F2: 0.25 µl
100 µM Primer R: 0.25 µl
10mM dNTPs: 0.5 µl
Taq: 1 µl
dH2O: 18.5 µl
(Total Volume = 25 µl)
Oct4 PCR Cycle (Reactions 1 and 2)
1. 94°C: 4 min
2. 94°C: 30 s
3. 56°C: 1 min (-1°C for each cycle)
4. 72°C: 1 min
5. Repeat steps 2-4 4X more
6. 94°C: 30 s
7. 51°C: 45 s
8. 72°C: 1 min 20 s
9. Repeat steps 6-8 29X more
10. 72°C: 10 min
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H19 PCR Reaction 1
Template DNA: 4 µl
10X Buffer: 5 µl
50 mM MgCl2: 2 µl
100 µM Primer F1: 1 µl
100 µM Primer R1: 1 µl
10mM dNTPs: 1 µl
Taq: 1 µl
dH2O: 35 µl
(Total Volume = 50 µl)
H19 PCR Reaction 2
Template DNA (from reaction 1): 2 µl
10X Buffer: 5 µl
50 mM MgCl2: 2 µl
100 µM Primer F2: 1 µl
100 µM Primer R2: 1 µl
10mM dNTPs: 1 µl
Taq: 1 µl
dH2O: 37 µl
(Total Volume = 50 µl)
H19 PCR Cycle (Reaction1):
1. 94°C: 4 min
2. 55°C: 2 min
3. 72°C: 2 min
4. Repeat steps 1-3 1X more
5. 94°C: 1 min
6. 55°C: 2 min
7. 72°C: 2 min
8. Repeat steps 5-7 34X more
9. 72°C: 10 min
H19 PCR Cycle (Reaction 2):
1. 94°C: 1 min
2. 55°C: 2 min
3. 72°C: 2 min
4. Repeat steps 1-3 34X more
5. 72°C: 10 min
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A region of the Oct4 promoter was amplified using two forward primers (F1 and
F2) and one reverse primer (R): F1 (GTTGTTTTGTTTTGGTTTTGGATAT), F2
(ATGGGTTGAAATATTGGGTTTATTTA) and R (CCACCCTCTAACCTTAACCTC
TAAC) (Blelloch, Wang et al. 2006).  The H19 DMR regions was amplified using
two forward primers (F1 and F2) and two reverse primers (R1 and R2): F1 (GAG
TAT TTA GGA GGT ATA AGA ATT), F2 (GTA AGG AGA TTA TGT TTA TTT
TTG G), R1 (ATC AAA AAC TAA CAT AAA CCC CT) and R2 (CCTCATTAATCC
CATAACTAT) (Lucifero, Mertineit et al. 2002).  All products from the second
PCR reactions were run on a 1% gel, purified using a gel purification kit (Qiagen)
and Topo-cloned into pCR2.1 vector.  The colonies were grown on LB plates
containing X-Gal to screen for white colonies that would contain an insert of the
purified PCR product.  These colonies were grown in liquid cultures and DNA
was extracted from them and sequenced using an M13 Reverse primer.  The
DNA sequences were aligned to the corresponding Oct4 or H19 regions and
analyzed for their methylation status using the program Sequencher 4.7.
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Chapter 4
Perspectives
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Genome-wide Approaches to Identify Protein-DNA Interactions
The last decade has seen the insurgence of a number of chromatin
immunoprecipitation (ChIP)-based technologies to facilitate the identification of
genomic binding targets of proteins, such as transcription factors.  These regions
can be identified by hybridizing ChIP DNA to array platforms (ChIP-chip) (Horak
and Snyder 2002), or through sequencing based technologies, such as ChIP-
PET (Loh, Wu et al. 2006), ChIP-SACO (Impey, McCorkle et al. 2004) and ChIP-
STAGE (Bhinge, Kim et al. 2007).  Most recently, ChIP-Seq was introduced as a
sequencing based method to examine protein-DNA binding events throughout
the genome (Johnson, Mortazavi et al. 2007).  This technology combines the
next-generation Solexa sequencing method (Bentley 2006) with traditional ChIP,
in order to obtain short sequence reads that can be mapped to the reference
genome to identify ChIP-enriched fragments.  This method offers several
advantages over ChIP-chip, including more rapid and extensive genome
coverage, as well as higher resolution of binding sites.  The sequencing method
used in ChIP-seq also provides greater sequencing depth than ChIP-PET, and
does not involve the cloning of ChIP-enriched DNA.  Therefore, it is likely that in
the near future, newer technologies like ChIP-seq are going to be used instead of
more traditional array and sequencing based methods to identify protein-DNA
interactions in a more rapid and comprehensive manner.
As newer technologies emerge, there is a need to assess the advantages and
limitations of each platform, and compare and integrate data obtained from them
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with previously known results.  Chapter 2 discusses ways in which such analyses
can be done for data obtained for the embryonic stem (ES) cells transcription
factors, Oct4 and Nanog from two platforms, ChIP-chip and ChIP-PET.  The
results of this study indicated that the data set from each platform was only a
partial representation of the overall network, and these data should be used in a
complementary fashion to obtain a more thorough overview of the transcriptional
circuitry.  These results also stress the need for performing such comparative
analyses to assess protein-DNA interaction data from other emerging platform
technologies, such as ChIP-seq.  Since the methods for performing such
assessments are discussed in greater detail in Chapter 2, the remainder of this
section will focus on the uses and limitations of ChIP-based genome-wide
approaches for identifying protein-DNA interactions.
Uses of ChIP-based Approaches in Examining Protein-DNA Interactions
The availability of whole genome sequences for different organisms has paved
the way for genome-wide analyses of DNA-binding factors, largely based on the
ChIP-based approaches mentioned earlier.  These studies have been
instrumental in the identification of DNA-binding patterns of a number of proteins,
such as transcription factors and chromatin-remodeling and modification
complexes, in simple organisms like yeast (Lee, Rinaldi et al. 2002), as well as in
mammalian systems (Horak, Mahajan et al. 2002; Odom, Zizlsperger et al.
2004).    For example, ChIP-chip studies on determining transcriptional regulation
by the Polymerase III machinery (RNA Polymerase III, TFIIIB and TFIIIC)
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identified a number of target genes that encode untranslated RNAs.
Furthermore, under starvation conditions, the expression of these RNAs was
regulated by inhibiting the recruitment of RNA Polymerase III and TFIIIB to these
sites.  However, TFIIIC remained bound to this set of target genes (Harismendy,
Gendrel et al. 2003; Roberts, Stewart et al. 2003; Moqtaderi and Struhl 2004).
Therefore, these studies demonstrate the manner in which ChIP-chip can be
used to examine the patterns of gene regulation by different components of the
transcriptional machinery under varying cell states and conditions.  Such ChIP-
based, genome-wide investigations can be expanded to other model organisms,
as well as in vitro systems such as ES cells, to explore the manner in which
different DNA-binding factors modulate gene expression patterns under a wide
variety of conditions.
Validation of Data Obtained from Genome-Wide Protein-DNA Interaction Studies
It is worth appreciating that even though such genome-wide approaches yield
vast amounts of information on protein-DNA interactions, the functional relevance
of these binding events must still be validated.  Approaches, such as RNAi can
be used as starting points for performing such analyses, by knocking down the
expression of genes that are bound by the protein of interest. Certain genomic
targets of the transcription factors Oct4 and Nanog, such as rif1 and esrrb have
been examined in this manner to investigate their roles in maintaining ES cell
pluripotency (Loh, Wu et al. 2006).  Such loss-of-function analyses can also be
carried out in a high throughput manner using genome-wide RNAi libraries.
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However, in mammalian systems, these large-scale studies are currently feasible
only in cells that can be cultured in vitro, e.g. ES cells.  Therefore, in order to
characterize these genomic targets at the organismal level, gene knockouts and
overexpression analyses must be done using conventional transgenic methods.
Since the design and characterization of transgenic animals is a time- and labor-
intensive process, it is often not feasible to validate all targets obtained from
these genome-wide ChIP-based methods.  This limitation poses a major
bottleneck in the extraction of biologically relevant information from these binding
data.  In the case of Oct4 and Nanog binding events in ES cells, one possible
way to prioritize genetic targets for validation would be to first examine those that
are conserved between human and mouse ES cells.  Given the similarity in
properties of ES cells derived from the two species, it is likely that these key
transcription factors act in similar ways in both types of ES cells.  For this
purpose, it will be advantageous to determine the overlap between the binding
data for both species, which was obtained using comparable platforms (e.g.
ChIP-chip).  However, this technique of target prioritization based on
conservation across species has the disadvantage of eliminating targets that may
account for the differences in the properties of human and mouse ES cells, and
have important roles in pluripotency. Therefore, in the future, shifting the focus of
high-throughput technology development, from target identification to target
validation will be essential in order to use these data to reach meaningful
conclusions.  Nevertheless, ChIP-based analyses have provided significant
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advancements in putting together protein-DNA interaction maps, which can be
used as starting frameworks for deciphering mechanisms of gene regulation.
Limitations of ChIP-Based Approaches
Despite the wealth of protein-DNA interaction information obtained from ChIP-
based studies, these analyses pose several limitations that remain to be
addressed.  One of these challenges stems from the use of formaldehyde as an
agent to cross-link proteins to DNA.  Since formaldehyde can create protein-
protein and protein-DNA crosslinks, the interaction data obtained from studies
can represent both direct as well as indirect associations between proteins and
DNA.  Moreover, proteins that are otherwise unbound to chromatin can also get
cross-linked to it, depending on their proximity to the surrounding DNA and
proteins.  Therefore, the development of protocols, where proteins can be
efficiently immunoprecipitated along with the interacting DNA fragments would be
extremely useful in addressing some of these issues.  Additionally, since laser-
induced UV rays only crosslink proteins to DNA, if methods to reverse such
crosslinks can be developed, this technique can be used to distinguish between
direct and indirect protein-DNA interactions (Hockensmith, Kubasek et al. 1991).
Aside from the technical issues of the ChIP procedure, one of the other hurdles
with obtaining protein-DNA interaction data is that the binding of several proteins,
such as transcription factors varies during different stages of the cell cycle.
Therefore, synchronization of cells to the same stage of the cell cycle is often
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necessary to address this issue.  However, it is not feasible to grow cells, such
as ES cells in this manner, thereby making the interpretation of protein-DNA
interaction data from these unsynchronized cells more tedious.  Moreover, these
interactions can also vary with changes in the cell’s chromatin state.  For
instance, the association of certain chromatin proteins with DNA is hyperdynamic
in ES cells, and can be difficult to capture using ChIP (Meshorer, Yellajoshula et
al. 2006).
One of the most important limitations with interpreting binding data is that it often
difficult to determine the regulatory role for a binding event.  This is particularly
true for a number of transcription factors, which not only bind promiscuously
throughout the genome, but can also regulate transcription from sites far away
from the target gene promoters.  Such gene regulation has been observed for the
transcription factors, c-Myc and p53, whose DNA-binding sites are located in
regions that are distant from the promoters of protein-coding genes (Cawley,
Bekiranov et al. 2004).  Similar to transcriptional mechanisms observed in
prokaryotes (Mossing and Record 1986), eukaryotic transcription factors may
also employ methods, such as forming DNA loops to regulate genes at distant
sites.  In order to address this issue, it will be important to determine the proteins
interacting with a transcription factor that impart specificity to its gene-regulatory
functions. An attempt at identifying proteins interacting with the ES cell
transcription factor, Nanog has been described in the Appendix.  Combining
protein-protein interaction information with protein-DNA binding data will provide
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better insight into the mechanisms by which a transcription factor can modulate
the downstream components of its regulatory network.
The Future of iPS Cell Technology: Designing Reprogramming and
Differentiation Screens
Recently, the use of four transcription factors to induce somatic cells into a
pluripotent state, has been used to address the issue of reprogramming, one of
the biggest challenges in ES cell biology (Takahashi and Yamanaka 2006;
Maherali, Sridharan et al. 2007; Okita, Ichisaka et al. 2007; Wernig, Meissner et
al. 2007).  This technique involves virus-mediated transduction of transgenes
encoding the transcription factors, Oct4, Sox2, c-Myc and Klf4 into somatic cells,
followed by selection for the activation of pluripotency markers in order to obtain
induced pluripotent (iPS) cells.  Even though this technique of reprogramming is
a major technological feat, as discussed in Chapters 1 and 3, the use of viral-
infection methods poses a significant challenge in the application of iPS cells in
medical therapies.  Therefore, safer non-viral substitutes must be devised for
reprogramming somatic cells into a pluripotent state.  To this end, it would be
desirable to gain further insight into the mechanism of reprogramming, by
defining intermediate steps in the process.  Furthermore, in order to use iPS cells
for therapeutic purposes, differentiation screens need to be designed, in order to
obtain a variety of patient-specific cell types that can be used in the treatment of
different diseases.
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The classification of steps in the reprogramming process, as well as the design of
differentiation screens will need an appropriate choice of markers.  For instance,
the activation of pluripotency factors, such as Nanog is used to select for cells
that have been completely reprogrammed to a pluripotent state. Moreover, as
shown in Chapter 3, the activation of fbx15, a target of Oct4 can also be used to
select for reprogramming.  However, the reasons for why more drug-resistant
colonies are obtained with Fbx15 selection than with Nanog selection are still
unclear.  It will be interesting to examine this issue by introducing an Oct4-GFP
marker in both types of cells, and analyzing the number of completely
reprogrammed cells in each case (as indicated by activation of GFP).  Such an
experiment will tell us whether Fbx15 selection leads to an enrichment for
completely reprogrammed iPS cells, or partially reprogrammed intermediates.
Additionally, the ChIP-based studies described in Chapter 2 identify a number of
downstream targets of the factors, Oct4 and Nanog in ES cells.  Some of these
genes, which are transcriptionally activated by Oct4 and Nanog, may be useful
markers for classification of intermediates in reprogramming.  Moreover, Oct4
and Nanog also bind to a number of genes that are silent in pluripotent cells, but
are expressed upon differentiation into specific cells lineages.  Therefore, such
genes could be used in differentiation screens in order to select for cells that
have differentiated into specific lineages, and express these markers.
Reprogramming and differentiation screens can be designed using both chemical
and biological approaches.  Chemical screens can be used to identify small
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molecule compounds that can successfully reprogram somatic cells into iPS
cells, and differentiate iPS cells into other specific cell lineages.  Additionally, a
number of developmentally important signaling pathways, such as Wnt (Cole,
Johnstone et al. 2008), JAK/STAT (Niwa, Burdon et al. 1998; Matsuda,
Nakamura et al. 1999)and NF-κB (Torres and Watt 2008), are known to regulate
pluripotency, as well as differentiation.  Therefore, another approach to designing
reprogramming and differentiation screens would be to identify chemical and
biological molecules (e.g. antibodies) that specifically target components of these
pathways.  The use of such multiple, parallel approaches will allow us to
determine safe and efficient ways in which pluripotent cells can be obtained and
employed in the treatment of a number of medical disorders.
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INTRODUCTION
This study aims to gain insight into the regulation of pluripotency by identifying
the proteins interacting with the pluripotency factor Nanog in murine embryonic
stem (ES) cells.  Nanog is a novel homeodomain transcription factor, and has
been shown to play a key role in maintaining ES cell identity as well as in early
cell fate decisions in the developing embryo (Chambers, Colby et al. 2003;
Mitsui, Tokuzawa et al. 2003).  Along with Oct4, Nanog is one of the earliest
expressed transcription factors known to be critical for developmental fate
decisions, since embryos and ES cells deficient for Nanog differentiate into
primitive endoderm (Chambers, Colby et al. 2003; Mitsui, Tokuzawa et al. 2003).
Expression analyses of Nanog have suggested a dual role for the protein in
maintaining not only an undifferentiated state but stem cell self-renewal as well.
In the preimplantation embryo, nanog’s expression begins in the inner cells of the
morula and is ultimately downregulated by early post-implantation stages when
the epiblast differentiates into different germ lineages.  Nanog is expressed
predominantly in pluripotent cells, including cells of the inner cell mass (ICM), ES
cells, embryonic germ cells, proliferating germ cells and embryonic carcinoma
cells (Chambers, Colby et al. 2003; Mitsui, Tokuzawa et al. 2003; Wang, Tsai et
al. 2003; Hart, Hartley et al. 2004; Yamaguchi, Kimura et al. 2005).  Interestingly,
ES cells that overexpress Nanog can bypass the otherwise essential stimulation
by the cytokine Leukemia Inhibitory Factor (LIF), which activates the transcription
factor Stat3 to maintain self-renewal (Niwa, Burdon et al. 1998; Matsuda,
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Nakamura et al. 1999; Chambers, Colby et al. 2003).  Hyperactivation of Stat3
has no effect on the endogenous levels of Nanog, indicating that Nanog’s role in
regulating self-renewal is independent of Stat3.
The ability to sustain ES cell self-renewal in the absence of LIF is a unique
property of Nanog, additional to its known function of preventing differentiation.
Therefore, Nanog may play a bifunctional role – one as an activator of self-
renewal genes and the other as a repressor of differentiation genes (Pan and Pei
2003; Pan and Pei 2005).  Currently, most evidence suggests that Nanog acts as
a repressor of differentiation.  The DNA recognition motif of Nanog is present in
the promoter of gata6, an inducer of primitive endoderm differentiation (Mitsui,
Tokuzawa et al. 2003).  Activation of the GATA factors, GATA4 and GATA6, is
required for differentiation into primitive endoderm (Fujikura, Yamato et al. 2002).
Forced expression of these factors leads to spontaneous differentiation into
primitive endoderm.  In fact, nanog deficient cells, which have a similar
phenotype show upregulation of these GATA factors.  It remains to be seen if
indeed Nanog blocks the effects of GATA6 and GATA4 in order to maintain
pluripotency.  Although there has been no in vivo evidence of Nanog acting as a
transcriptional activator, luciferase reporter assays indicate that Nanog can
activate transcription via its C-terminal domain (Pan and Pei 2005).  Further
investigations of how Nanog can activate or repress the transcription of its
targets are required to establish its suggested bifunctional role in sustaining
pluripotency.
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This project aims to gain better insight into the mechanism by which Nanog
regulates the transcription of its targets by identifying physiologically relevant
binding partners of Nanog in ES cells.  In order to accomplish this goal, a
functional FLAG-HA epitope-tagged construct of Nanog was generated and
targeted to the endogenous Nanog locus.  We purified proteins associated with
Nanog from ES cells expressing this tagged construct, and identified these using
mass spectrometry.  Our preliminary data include the proteins BAF60b, γ-catenin,
histone variant H2A.Z, Myb binding protein and eIF4a3. Further validation of
these protein interactions, and an examination of their roles in the maintenance
of pluripotency will lead to a better understanding of the mechanism by which the
transcription factor Nanog regulates cell-fate determination.
RESULTS
Generation of FLAG-HA Tagged Nanog constructs
Four different constructs were generated with nanog cDNA tagged with FLAG
and HA epitopes (Figure 1a).  Two of these had the FLAG-HA sequences tagged
to the N-terminus of the nanog cDNA, and the other two had these tags on the C-
terminus end.  One N-terminally tagged construct and another C- terminally
tagged one were targeted downstream of the nanog promoter, These constructs
were termed Nanog FH(N) and Nanog FH(C), respectively.  The other two
constructs were inserted into an overexpression cassette, under the control of
the ubiquitously strong CAGGS promoter.  These constructs, hereafter referred
to as CAGGS Nanog FH(N) (for the N-terminally tagged construct) and CAGGS
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Nanog FH(C) (for the C-terminally tagged construct), were targeted downstream
of the collagen1a1 locus (used for high targeting efficiency) using FLP/frt
mediated site-specific integration.
The constructs Nanog FH(N) and Nanog FH(C) were targeted to V6.5 ES cells,
and CAGGS Nanog FH(N) and CAGGS Nanog FH(C) were targeted to C10 ES
cells, which contained an frt site at the collagen1a1 locus.  After drug selection,
all clones were screened by Southern blot analyses to check for correctly
targeted ES cells (Figure 1b).  An external probe in the 3’ end of nanog intron 1
was used to screen targeted with the Nanog FH(N) and Nanog FH (C)
constructs, where a 6.4 kb band represented the wild-type nanog allele, and a
4.7 kb one represented the targeted one.  A 5’ end internal probe from the Nanog
promoter was also used to screen these ES cells, and in this case, the wild-type
nanog allele gave a 6.4 kb band, and the targeted allele gave a 2.7 kb one.
Using this strategy, 4 out of 48 clones for Nanog FH (N) and 6 out of 48 for
Nanog FH(C) were determined as correctly targeted.  ES cells targeted with the
overexpression constructs were screened with an internal 3’ probe, where the
wild-type allele gave a 6.2 kb band, the frt allele gave a 6.7 kb band and a
correctly targeted flp-in allele gave a 4.1 kb band.  All resistant ES cell colonies
for CAGGS Nanog FH(N) (I out of 1) and CAGGS Nanog FH(C) (20 out of 20)
were correctly targeted.
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Figure 1.  FLAG-HA Epitope Tagged Nanog Constructs.  (a) The four
targeting constructs of Nanog tagged with FLAG and HA epitopes at the N- or C-
termini and targeted to the nanog or collagen1a1 locus.  (b) Southern blot
analyses to screen for ES cells clones correctly targeted with the tagged Nanog
constructs.  Lanes with DNA from correctly targeted ES cell clones are labeled ‘T’
and untargeted wild type controls are labeled ‘WT’.  In Southerns (i) and (iii), the
wild type locus produced a 6.4 kb band and the targeted one produced a 4.7 kb
band.  In Southerns (ii) and (iv), the wild type locus produced a 6.4 kb band and
the targeted one produced a 2.7 kb one.  In Southern (v) the wild type locus is
represented by a 6.2 kb band and the targeted one produced a 4.1 kb band.  In
this blot, ‘T(C)’ represents correctly targeted CAGGS Nanog FH(C), and ‘T(N)’
represents correctly targeted CAGGS Nanog FH(N).
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LIF-Independence Functionality Tests for Tagged Nanog Constructs
In order the check for the functionality of the N- and C-terminally tagged Nanog
constructs, we utilized the ability of ES cells that overexpress Nanog to grow in
the absence of LIF.  In this assay, the ES cells targeted with the overexpression
constructs provided a functional assay for the tagged proteins.  All four types of
targeted ES cell lines, Nanog FH(N), Nanog FH(C), CAGGS Nanog FH(N) and
CAGGS Nanog FH(C), as well as untargeted V6.5 ES cells were grown in the
presence and absence of LIF (Figure 2a).  All ES cell lines grew stably in the
presence of LIF.  When LIF was withdrawn from the growth media, the cells
expressing Nanog at endogenous levels differentiated, but the CAGGS Nanog
FH(C) ES cell line remained undifferentiated.  Surprisingly, the CAGGS Nanog
FH(N) ES cell line that overexpressed Nanog tagged at the N-terminus failed to
self-renew in the absence of LIF.  Therefore, C-terminally tagged Nanog was
determined to be functional, whereas the N-terminally tagged Nanog construct
was not.  All subsequent experiments were carried out with the C-terminally
tagged Nanog ES cells.  These cells produced Nanog protein that was detectable
by western blots using anti-Nanog and anti-HA antibodies (Figure 2b)
Immunoprecipitation of Nanog and Associated Proteins from ES cell
Nuclear Extracts
Nuclear and cytoplasmic extracts were made from the CAGGS Nanog FH(C) and
Nanog FH(C) ES cell lines.  Western blots of these fractions performed with an
anti-HA antibody revealed that the tagged Nanog transcription factor, which is a
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nuclear protein was being sequestered into the cytoplasm in the overexpression
CAGGS Nanog FH(C) ES cell line (Figure 2c).  Since such sequestering can lead
to excessive background, we conducted the large-scale purifications with nuclear
extracts from the Nanog FH(C) cell line that expressed Nanog at endogenous
levels.
Before proceeding with large-scale purifications of Nanog, preliminary
immunoprecipitations were performed with an anti-FLAG antibody on whole cell-
extracts from the Nanog FH(C) and CAGGS Nanog FH(C) ES cell lines.
Western blot analyses on the immunoprecipitated material with anti-HA and anti-
Nanog antibodies confirmed that the tagged protein of approximately 39 kDa
could be pulled down from these cells.  No protein was detectable in similar
immunoprecipitations performed with untagged V6.5 ES cells (Figure 2d). Large-
scale anti-FLAG immunoprecipations were performed on approximately109
Nanog FH(C) ES cells and V6.5 control ES cells, and the eluates in each case
were analyzed by mass spectrometry.  Background proteins identified in the V6.5
ES cells were eliminated from the proteins identified in the Nanog FH(C)
immunoprecipitated material.  These analyses identified the proteins H2A.Z,
Baf60b, Myb-binding protein, γ-catenin and eIF4a3 as ones that interacted with
Nanog.
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Figure 2.  Characterization of Tagged Nanog ES cells.  (a) LIF-independence
tests to examine functionality of tagged Nanog constructs.  Nanog FH(C),
CAGGS Nanog FH(C), Nanog FH(N), CAGGS Nanog FH(N) and untagged V6.5
ES cells were grown in the presence (+) or absence (-) of LIF.  (b) Western blots
with anti-Nanog (top gel) and anti-HA (bottom gel) antibodies to show Nanog
expression (39 kDa band) in Nanog FH(C), CAGGS Nanog FH(C) and untagged
E14 ES cells.  Ponceau stained membranes to check for equal protein loading
are shown to the right of each gel.  (c) Western blots with anti-HA antibody
showing Nanog expression (39 kDa band) in (i) CAGGS Nanog FH(C) nuclear
extract (lane 1) and cytoplasmic extract (lane 2), as well as in (ii) V6.5 ES cell
nuclear extract (lane 1), cytoplasmic extract (lane 2) and Nanog FH(C) nuclear
extract (lane 3) and cytoplasmic extract (lane 4).  Beta-Actin loading controls are
shown for each gel. (d) Western blots with anti-Nanog antibody (left) and anti-HA
antibody (right) following anti-FLAG immunoprecipitations in untagged V6.5 ES
cells, Nanog FH(C) and CAGGS Nanog FH(C) ES cells.  Nanog protein is
represented by a 39 kDa band.    
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DISCUSSION
This project aimed at identifying proteins interacting with Nanog in mouse ES
cells, in order to gain further insight into the mechanism by which this
transcription factor regulates the expression of its targets to maintain
pluripotency.  In order to address this issue, we employed a strategy that
involved immunoprecipitation of Nanog and associated proteins from ES cells
expressing FLAG-HA epitope tagged Nanog from the endogenous nanog locus.
The proteins interacting with Nanog were identified by mass spectrometry.  Using
this approach, we identified five potential candidates that interact with Nanog—
Histone variant H2A.Z, Myb-binding protein 1a (Mybb1a), γ-catenin, BAF60b and
eIF4a3.
Although the results of these experiments must be reproduced and validated,
some of the candidate proteins identified seem to have functions that may be
interesting and relevant to pluripotency and early cell fate decisions.  For
instance, the histone H2A.Z, which is a variant of histone H2A, has been shown
to be critical for early mammalian development and ES cell pluripotency (Faast,
Thonglairoam et al. 2001).  Interestingly, the H2A.Z knockout embryo
phenocopies a nanog knockout embryo, since both die between days 3.5 and 4.5
postcoitum and differentiate into primitive endoderm. Similarly, ES cells deficient
for H2A.Z or Nanog also differentiate into primitive endoderm.  A role for H2A.Z
has been suggested in transcriptional regulation, since it is essential in
maintaining an active chromatin state and preventing the spread of
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heterochromatin (Fan, Gordon et al. 2002).  Therefore, it will be interesting to
further validate the association between H2A.Z and Nanog in ES cells, and
examine the relevance of this interaction with respect to pluripotency.
Another protein that was identified as a factor interacting with Nanog was
Mybbp1a.  Although this protein has been previously shown to regulate
transcription by binding to the transcription factor, c-Myb (Tavner, Simpson et al.
1998), it was also identified as a novel repressor of NF-κB activity (Owen, Elser
et al. 2007).  Interestingly, in recent studies, Nanog was also shown to maintain
ES cell pluripotency by inhibiting NF-κB activity (Torres and Watt 2008).
Therefore, if the interaction between Mybbp1a and Nanog can be validated, it
could lend further insight into the mechanism of transcriptional regulation by
Nanog.
For the remaining factors that were pulled down with Nanog in our experiments,
their roles in transcriptional regulation and ES cell pluripotency need to be further
explored. γ-catenin has been shown to be share sequence similarity with the
transcription factor β-catenin, but its role in activating the Wnt/TCF/Lef pathway is
still unclear (Shimizu, Fukunaga et al. 2008).  Recent studies indicate that Nanog
shares a number of its downstream genomic targets in ES cells with those of
Tcf3, a component of the Wnt signaling pathway (Cole, Johnstone et al. 2008).  It
would be of interest to examine the potential involvement of γ-catenin in
mediating such transcriptional regulation.  There is little known about the roles of
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BAF-60b (Wang, Xue et al. 1996), a component of the Swi/Snf complex, and
eIF4A3 (Chan, Dostie et al. 2004), a component of the exon-junction complex
with respect to transcriptional regulation or maintenance of pluripotency.
In the future, the Nanog-interacting factors identified in these experiments should
be reproduced in multiple immunoprecipitations, and validated by other methods
such as co-immunoprecipitations or gel-shift assays.  It would also be interesting
to examine whether these proteins are bound to Nanog freely in the nucleus, or
on chromatin, and whether they form one or more complexes with Nanog.  The
stoichiometry of the components of such a complex (or complexes) should be
determined.   Importantly, characterizing the relevance of these interactions to
transcriptional regulation and the maintenance of pluripotency will provide a
better understanding of the molecular mechanisms by which the transcription
factor Nanog can regulate cell fate decisions.
METHODS
Generation of FLAG-HA Tagged Nanog constructs for Endogenous
Expression and Overexpression
(i) Cloning of Nanog FH(N) and Nanog FH(C) Targeting Constructs
The initial cloning vector for both constructs was generated by subcloning a
PGK-neomycin cassette flanked by 2 loxP sites into a pSP72 vector with BamHI
and XhoI.  For both targeting vectors, the 5’ arm, the tagged nanog cDNA, and
an RBGpA sequence were inserted between this BamHI site, and a ClaI site in
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the pSP72 vector.  The 5’ arms of both vectors spanned 1188 bp of the nanog
promoter and were flanked by a ClaI site at the 5’ end and a BamHI site at the 3’
end.  These restriction sites were added to the PCR primers that were used for
amplifying the 5’ arm from a BAC containing this region of the nanog promoter.
The primers for the 5’arm PCR were: Forward (ATCGATCTGGGTTAGAGTGCT
TTCACTCAC) and Reverse (GGATCCGTCAGTGTGATGGCGAGGGAAGGG).
The nanog cDNA tagged with FLAG and HA sequences at either the N- or C-
terminus was cloned downstream of the 5’arm.  These cDNAs were flanked by a
BamHI site at the 5’end and an XbaI site at the 3’ end.  These restriction sites, as
well as the FLAG and HA epitope tags were added to the PCR primers used for
amplification of the cDNAs.  For the Nanog FH(N) cDNA, the PCR primers were:
Forward (GGATCCGCTCGATGAACCATGGACTACAAGGACGACGATGACAA
GCTCGATGGAGGATACCCCTACGACGTGCCCGACTACGCCAGTGTGGGTC
TTCCTGGTCCCCACAGTTTGCC) and Reverse (TCTAGATCATATTTCACCTG
GTGGAGTCAC), and for the Nanog FH(C) cDNA, the primers used were:
Forward (GGATCCATGAGTGTGGGTCTTCCTGGTCCC) and Reverse (TCTAG
ACTAGGCGTAGTCGGGCACGTCGTAGGGGTATCCTCCAGCGGCCGACTTG
TCATCGTCGTCCTTGTAGTCTATTTCACCTGGTGGAGTCACAGAGTAGTTCA
GG).  The FLAG and HA sequences used for cloning have been described
earlier (Nakatani and Ogryzko 2003).  For the N-terminal tag, a Kozak sequence
was also included as suggested in this paper.  For both Nanog FH(N) and Nanog
FH(C), an RBGpA sequence was cloned downstream of the tagged cDNAs using
an XbaI site at the 3’end of the cDNAs and a BamHI site at the 5’end of the
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PGKneo2lox fragment.  The 3’ arm for both targeting vectors was amplified from
a BAC, and spanned 1.4 kb of nanog intron 1.  The PCR primers used for the 3’
arm were: Forward (GCGGCCGCGTAAGGAATTCAGTCCCCGAA) and Reverse
(GCGGCCGCCTCGAGGCCCTCTTCTGGAGTGTCTGAAGAC).  For Nanog
FH(N), the 3’arm was cloned into the targeting vector with a NotI site at the 5’
end and XhoI site at the 3’ end.  In the case of Nanog FH(C), this arm was
cloned into the vector using the XhoI restriction site.
(ii) Cloning of CAGGS Nanog FH(N) and CAGGS Nanog FH(C) Flp-in Constructs
In order to obtain the CAGGS Nanog FH(N) construct, the N-terminally tagged
nanog cDNA that had been PCR-amplified and TOPO cloned into pCR2.1, was
subloned into the EcoR1 site of the vector PGK(ATG)frt-CAGGS-RBGpA through
blunt end ligation.  The C-terminally tagged cDNA was isolated from an
XbaI/BamHi/BglII digest of Nanog FH(C), and gel-purifying a 990 bp fragment
that represented the cDNA.  This cDNA was also cloned into the EcoRI site of
PGK(ATG)frt-CAGGS-RBGpA through blunt end ligation, in order to get the
CAGGS Nanog FH(C) construct.
Targeting of FLAG-HA Tagged Nanog Constructs to ES Cells
(i) Targeting of Nanog FH(N) and Nanog FH(C)
25 µg each of Nanog FH(N) and Nanog FH(C) targeting vectors were linearized
with PvuI in 500 µl reactions.  The digested DNA was ethanol precipitated,
resuspended in 50 µl of T.E.buffer (10 mM Tris-HCl (pH 7.5), 0.1 mM EDTA) and
167
electroporated into 106 v6.5 ES cells, by zapping twice at 400V and 25 µF.
These electroporated ES cells were selected with neomycin (350 µg/ml) for 10
days, starting at 24 hours after electroporation.  Neomycin resistant clones were
picked and expanded for screening with Southern blot analysis.
(ii) Targeting of CAGGS Nanog FH(N) and CAGGS Nanog FH(C)
50 µg each of CAGGS Nanog FH(N) and CAGGS Nanog FH(C) were ethanol
precipitated along with 25 µg of the pCAGGS flpE recombinase plasmid.  The
precipitated DNA in each case was resuspended in 400 µl of HEPES buffer and
electroporated into 106 C10 ES cells (Beard, Hochedlinger et al. 2006) by
zapping twice at 500V and 25 µF.  The electroporated ES cells were selected
with hygromycin (140 µg/ml) for 13 days, starting at 24 hours after
electroporation.  Drug-resistant clones were picked and expanded for screening
by Southern blots.
Southern Blot Analyses to Screen for Correctly Targeted FLAG-HA Tagged
Nanog Constructs
(i) Southern Blot Analyses for Nanog FH(N) and Nanog FH(C) Targeted ES cells
In order to screen for ES cells targeted with the Nanog FH(N) and Nanog FH(C)
constructs, DNA from neomycin-resistant ES cell clones was digested with PvuII
and run on a 0.8% agarose gel.  For examining homologous recombination at the
3’ end, a 415 bp external probe was PCR-amplified from nanog intron 1 using the
primers: Forward (GCTACCTGAGACCCTATCCCTTAG) and Reverse
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(CATCTCACCAG CCCTACATACAGTG).  This probe identified a 6.4 kb band
representing the wild-type nanog allele, and a 4.7 kb band representing a
targeted allele (Nanog FH(N) or Nanog FH(C)).  In order to screen for 5’end
homologous recombination, an internal probe was isolated by purifying an
approximately 400 bp fragment from a PvuII/XbaI digest of the Nanog FH(C)
targeting vector.  This probe identified a 6.4 kb band representing the wild type
nanog allele and a 2.7 kb band representing the targeted allele (Nanog FH(N) or
Nanog FH(C)).
(ii) Southern Blot Analyses for CAGGS Nanog FH(N) and CAGGS Nanog FH(C)
Targeted ES cells
DNA from ES cell clones targeted with CAGGS Nanog FH(N) and CAGGS
Nanog FH(C) were digested with SpeI.  In order to generate a 3’ internal probe,
the Col1ABSKS plasmid was digested with PstI and XbaI, and an 850 bp
fragment was gel-purified.  This probe recognized a 6.2 kb band from the wild
type collagen1a1 allele, a 6.7 kb band of the frtpgkneo allele, and a 4.1 kb band
of the targeted allele.  Southern blots were carried out as described in Chapter 3.
LIF-Independence Functionality Tests for Tagged Nanog constructs
ES cells that were correctly targeted with the four tagged Nanog constructs, as
well as untagged V6.5 ES cells were cultured in duplicate 6-well dishes in ES
media containing LIF.  These cells had been passaged once without MEFs in
order to avoid LIF produced from the feeder layer.  After 48 hours, LIF was
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withdrawn from the media in half of the wells and the morphology of ES cells was
examined after another 48 hours.
Preparation of ES Cell Whole-cell, Nuclear and Cytoplasmic Extracts
(i) Preparation of ES Cell Whole Cell Extracts for Small Scale Protein
Purifications
ES cells were grown on one gelatin coated, 15 cm2 dish until they were
approximately 80% confluent.  The cells were grown without MEFs for at least
one passage to avoid feeder contamination.  The cells were washed twice with
cold 1X PBS, pH 7.4 and 500 µl of 1X Cell Lysis Buffer (Cell Signaling
Technology) was added to the ES cells. 1 mM PMSF and a protease inhibitor
cocktail (Roche) had been added to the lysis buffer immediately before use.  The
plate was incubated on ice for 5 minutes and cells were scraped using a
polyethylene cell lifter (Corning), and transferred into a 1.5 ml microcentrifuge
tube.  The extract was incubated on a rocker at 4°C, and spun for 10 minutes at
14000 RPM for another 10 minutes in a cold microcentrifuge.  The supernatant
was removed and either used immediately for further purifications, or flash frozen
in liquid N2 and stored at -80°C.  Bradford assays were used to determine the
protein concentration.
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Preparation of Nuclear and Cytoplasmic Extracts for Large-Scale Protein
Purifications
ES cells were grown on 25 gelatin coated, 15 cm2 dish until they were
approximately 80% confluent.  The cells were grown without MEFs for at least
one passage to avoid feeder contamination.  After this step, all procedures were
carried out in the cold room at 4°C.  The ES cells were washed twice with cold
1X PBS, pH 7.4.  5 ml of PBS were added to each plate, the cells were scraped
off with a polyethylene cell lifter (Corning), and transferred into a 250 ml
centrifuge tube (Corning).  The cells were spun at 3000 RPM for 5 minutes, and
the residual PBS was discarded. The packed cell volume (PCV) was measured
at this time and the extraction protocol described below was carried out.  The cell
pellets could also be flash frozen in liquid N2 at this point and stored at -80°C.
Buffers for Nuclear and Cytoplasmic Extract Protocol
High Salt Buffer
20 mM HEPES, pH 7.9, stored at 4°C
25% glycerol
1.5 mM MgCl2
1.2 M KCl
0.2 mM EDTA
0.5 mM PMSF (added dropwise before use)
1 mM DTT (added before use)
Hypotonic Buffer
10 mM HEPES, pH 7.9, stored at 4°C
1.5 mM MgCl2
10mM KCl
0.5 mM PMSF (added dropwise before use)
1 mM DTT (added before use)
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Low Salt Buffer
20 mM HEPES, pH 7.9, stored at 4°C
25% glycerol
1.5 mM MgCl2
0.02 M KCl
0.2 mM EDTA
0,5 mM PMSF (added dropwise before use)
1 mM DTT (added before use)
Isolation of Nuclei
1.  Resuspend the cell pellet in a 50 ml Falcon tube in 4X PCV of 1X PBS, pH 7.4
2.  Centrifuge the cells for 10 minutes at 3000 RPM using a JS4.2 rotor, and
remove the supernatant gently with a pipette.  Note:  A turbid supernatant
indicates cell lysis.
3.  Resuspend the cells rapidly in 2-3X PCV of hypotonic buffer and quickly
vortex for less than 10 seconds.
4.  Centrifuge the cells for 5 minutes at 3000 RPM, and discard the supernatant.
Note:  This step should also be carried out rapidly since proteins can leak out of
the cells.  This step removes the salt in the PBS in order for efficient swelling to
occur in the next step.  Some swelling is also seen at this stage.
5.  Resuspend the cells in 3X original PCV of hypotonic buffer and allow them to
swell on ice for 10 minutes.
6.  Transfer the cells to a glass Dounce homogenizer (15 ml capacity), and
homogenize the cells with 25 strokes of a type B pestle.  Note:  The pestle
should be moved up and down slowly to avoid air bubbles from forming.
7.  Check cells for lysis using Trypan Blue.  Mix 2.5 µl of cells with 20 µl of
Trypan Blue dye, and place them on a slide.  Cover the sample with a coverslip
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and observe it under a microscope.  The nuclei of lysed cells stain blue or purple.
Approximately 90% lysis should be seen after 25 strokes.
8.  Transfer the cells to a 50 ml Falcon tube and centrifuge for 15 minutes at
4000 RPM in a JS4.2 rotor.
9.  Remove the supernatant, which is the cytoplasmic extract.  This extract can
be flash frozen in liquid N2 and stored at -80°C.
Extraction of Nuclei
10.  Measure the packed nuclear volume (PNV) using the graduations on the
Falcon tube.  Resuspend the nuclei in 1/2 PNV of low salt buffer by vortexing
briefly.
11.  Hold the tube on a vortex with one hand, and while gently vortexing, slowly
and dropwise, add 1/2 PNV of high salt buffer.  Note:  Continuous mixing and
dropwise addition of high salt buffer is necessary to prevent nuclei from clumping
together.
12.  Use a rocking platform to gently mix the buffers and nuclei.  Let the
extraction continue for 30 minutes.  Note:  The extract should seem non-
homogenously viscous (mucus-like).
13.  Pellet the nuclei by centrifuging for 30 minutes in a Beckman JA-20 rotor at
14500 RPM.   Remove the supernatant, which is the nuclear extract.  This can be
flash frozen in liquid N2 and stored at -80°C, or used immediately for further
purification.  The nuclei in the pellet can also be similarly saved to obtain
chromatin extracts.
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Anti-FLAG Immunoprecipitation of Nanog
Note: All immunoprecipitation reactions were carried out at 4°C.
Small Scale Anti-FLAG Purification of Nanog from Tagged ES cells
1. Aliquot 40-50 µl of FLAG antibody beads slurry (Sigma) per sample.
2. Wash the slurry with twice the amount of 1X cold PBS and spin at 5000 RPM
for 1 min.
3. Repeat the wash after removing most of the PBS and adding more cold 1X
PBS.
4. Remove the PBS and add an equivalent amount of cold 1X PBS to the slurry
(i.e., if 250 µl of slurry is being used, then add 250 µl of PBS).
5. In fresh microcentrifuge tubes, add 80 µl of slurry for each sample.
6. Measure the protein concentration with a Bradford assay and aliquot the
desired amount of lysate to mix with the slurry.
7. Incubate the immunoprecipitation reactions at 4°C for 2 hours.
8. Prepare Elution Buffer: HEPES 50 mM (pH 7.4), 100 mM NaCl.  For protein
elution add 490 µl of elution buffer + 10 µl of 50X FLAG peptide (Sigma).
9. Spin immunoprecipitation reactions for 1 min at 5000 RPM.  Wait for a minute
for the beads to settle down and then remove most of the buffer,
10. Add 800 µl of 1% Triton buffer (wash buffer) and mix,
11. Spin at 5000 RPM for 1 min.  Wait for beads to settle, remove the buffer and
repeat the wash twice more with wash buffer.
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12. Repeat the wash with 800 µl of elution buffer (without the FLAG peptide).
Remove all the liquid with a 25 G needle.
13. Add 70 µl of elution buffer (with the FLAG peptide).  Use a tip cut off at the
end so that beads can be mixed well by pipetting.
14. Incubate at room temperature for 10 minutes.
15. Add 15 µl of 5X protein sample buffer (NuPage) to 60 µl of eluate, boil for 5
minutes and store at -80°C or use for further analyses.
16. Add 20 µl of sample buffer to the beads, boil them for 5 minutes and store in
the freezer or use for further analyses.
Large-Scale Anti-FLAG Immuno-affinity Purification of Tagged Nanog from ES
Cells
Reagents and Buffers for FLAG-IP Protocol
2X BC0
40% glycerol
40 mM HEPES, pH 7.9
0.4 mM EDTA
1 mM DTT
0.4 mM PMSF
BC100
50 ml 2X BC0
46 ml dH2O
4 ml 2.5 M KCl
100 µl 200 mM PMSF
50 µl 1 M DTT
BC150
50 ml 2X BC0
44 ml dH2O
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6 ml 2.5 M KCl
100 µl 200 mM PMSF
50 µL 1 M DTT
BC300
50 ml 2X BC0
38 ml dH2O
12 ml 2.5 M KCl
100 µl 200 mM PMSF
50 µl 1 M DTT
BC500
50 ml 2X BC0
30 ml dH2O
20 ml 2.5 M KCl
100 µl 200 mM PMSF
50 µl 1 M DTT
200 X TLCK
10 mg/ml in 1 mM HCl
Add protease inhibitor cocktail (Roche) to all solutions immediately before use.
Immunoprecipitation Protocol
1. To immunoprecipitate 3 samples, wash 1.5 ml (i.e. 3 ml of slurry) of FLAG M2
resin (Sigma) on a BioRad Polyprep chromatography column 3 times with BC150
(add 7.5 ml of BC150 to the resin, spin at 1000 RPM for 1 min and remove
supernatant).
2.  Incubate with 7.5 ml of 5X Denhardt’s Solution (USB) for 30 minutes.
3. Wash the resin twice more with 7.5 ml BC150.
4. Bring the total volume up to 4 ml and aliquot 1 ml in each of three 15 ml Falcon
tubes (leave 1 ml spare in case of pipetting errors).
5. Add 5 ml of BC150 to each tube and wash the resin one more time.
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6.  Add fortified nuclear extracts (including 0.2 mM DTT, 1X TLCK and protease
inhibitor cocktail (Roche)) to the washed resin and incubate on a rocker
overnight.
7. Pour the resin back into a polyprep column gently, by pouring along the edge
of the column (do not pipette, since this may damage the resin).
8. Collect the flow through, and towards the end add 1 ml of BC150 to the tube
and pour it into the column.  Note: Do not let the column dry out.
9. Add 250 µl of BC150 and let it soak in.  Repeat again with another 250 µl of
BC150.  Add 5 ml of BC150 and let it flow through the column.
Repeat the previous step with 500µl + 5 ml of BC300, BC500, BC300 and
BC100, in that order.
10. Elute the protein by using a 20:1 molar ratio of peptide to antibody (prepare a
stock solution of 2.5 mg of 3X FLAG peptide (Sigma) in 4.7 ml of BC100).  Add
150 µl of peptide (in BC100) to the column and incubate for 80 min by stopping
the column.  Layer on another 150 µl of peptide solution, and collect the flow
through.
11. Repeat the previous step four more times.
12. Combine the eluates from the last two steps and concentrate the volume to
100 µl using protein concentration columns (Vivaspin2, 5000 MWCO, PES).  The
eluates can be frozen at -80°C or sent for Mass spectrometry analysis for
identification of proteins present in the samples.
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Western Blot Analyses
100 µg of protein samples were run on 4-12% gradient NuPAGE (Novex) gels at
200V for 50 minutes in MOPS buffer.  The samples had been prepared with
NuPAGE sample buffer and 1/0th volume of DTT (according to specifications by
NuPAGE).  The proteins were transferred to a nitrocellulose membrane at 350
mA for 45 minutes at 4°C in transfer buffer (12 mM Tris. 96 mM glycine, 20%
methanol, pH 8.3).  The membrane was blocked in PBS+1% non-fat milk powder
for 15 minutes at room temperature.  It was incubated with primary antibody
diluted in PBS + 1% non-fat milk powder + 0.1% Tween-20 for 90 minutes at
room temperature.  The membrane was washed 3 times for 10 minutes with
PBS+ 0.1% Tween-20.  It was incubated with the secondary antibody diluted in
PBS+ 1% non-fat milk powder +0.1% Tween-20 for 1 hour at room temperature.
The membrane was washed 3 times for 10 minutes with PBS + 0.1% Tween-20
and developed using ECL reagent.
Antibodies
For western blots, the primary antibodies used were anti-Nanog antibody
(BL1162, Bethyl) anti-HA-HRP (3F10, Roche), anti-HA (Covance), anti-β-actin
(Abcam 8226).  HRP-conjugated rabbit and mouse secondary antibodies were
used from Santa Cruz.  For FLAG immunoprecipitations, anti-FLAG M2 affinity
gel (Sigma) was used.
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